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Abstract 
The purpose of this project was to investigate the interplay between gating window 
characteristics and target margin required to compensate for residual motion during the gating 
window. This project investigated the accuracy of ExacTrac and 4DCT imaging localizing an 
implanted coil at various phases of respiration. Radiochromic film measured delivered dose 
patterns for selected gating intervals over a variety of respiratory patterns. In order to establish 
accurate dosimetry, this project implemented and tested an EBT radiochromic film dosimetry 
system.  
Film testing showed that the performance of a medical grade Vidar Dosimetry Pro 
radiographic film scanner and an Epson V700 Photo flatbed scanner were very similar. Both 
scanners showed nearly the same performance in terms of measurement repeatability, noise, 
vertical and horizontal uniformity over a range of doses from 11.5-511.9 cGy. The Vidar was 
selected for these studies due to clinical availability. 
Even at the greatest coil velocities observed, ExacTrac coil localization agreed with 
calculated coil motion to within 0.8 mm. 4DCT showed errors up to 5.5 mm resolving coil 
position during large respiratory-induced velocities. 4DCT accurately measured the coil length 
within 1 mm of actual coil length at end expiration/inhalation. 4DCT can provide an accurate 
representation of the phantom at end-respiration for treatment planning purposes, and ExacTrac 
can accurately localize the coil to determine target motion in all phases 
For patient treatments it is suggested that target margins should be set using the residual 
motion during gating. For patients without implanted coils, the residual motion can be computed 
based on the target motion measured from 4DCT and the size of the gating window. For patients 
with implanted coils, the ExacTrac system can be used to directly measure residual tumor motion 
during gating.  
 xiii 
The hypothesis of this work was that gated delivery combined with 4DCT could limit 
internal margins to less than 3 mm while maintaining 95% prescription dose coverage of moving 
targets. The hypothesis was found to be true for gating windows of 10% and 20% for target 
motions up to 25 mm and was true with gating windows up to 50% for smaller motions (5 & 10 
mm). 
 
 
 1 
1 Introduction 
1.1 Statement of the Problem 
The American Cancer Society reports that in 2007, lung cancer accounted for 31% of all 
cancer deaths in the United States and an estimated 213,380 new cases were diagnosed (1.1). 
This report also states that the five-year survival rate for all stages of lung cancer combined is 
16%. However, there is clinical evidence that tumor control can be increased with an increase in 
treatment dose (1.2, 1.3, 1.4). One limiting factor in dose escalation is the risk of lung 
complications, which has been shown to correlate with the average lung dose and similar 
surrogates such as the volume of lung receiving ≥20 Gy (1.5, 1.6). The need for normal tissue 
sparing becomes even more important when concurrent chemotherapy is used. Thus, there is 
clinical evidence that technologies that increase dose to the tumor while sparing healthy tissues 
will improve the clinical outcomes for lung cancer patients.  
The goal of modern radiation therapy is to maximize the absorbed dose in a target 
volume while minimizing dose to normal, healthy tissue. Three-dimensional conformal radiation 
therapy (3DCRT) uses imaging studies such as computed tomography (CT) to define target 
volumes in three dimensions, and 3D treatment planning software to generate plans that conform 
the dose distribution as closely as possible to those volumes. Reductions in complications that 
result from irradiating healthy tissue can be achieved by limiting the dose delivered to normal 
tissue. With a relative reduction of dose to normal tissues comes the ability to escalate the dose 
delivered to the target to increase tumor control probability while maintaining acceptable levels 
of normal tissue complications. 
One major limitation of conventional 3DCRT is the lack of compensation for respiration-
induced organ motion. Current standard radiation therapy techniques treat a volume that 
encompasses the tumor at all potential positions within the respiratory cycle. While this 
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technique covers the tumor volume, it also dramatically increases the dose to surrounding normal 
tissues. Respiratory motion can potentially reduce the target localization accuracy of therapy 
delivered to tumor sites in the thorax and abdomen. Accurate knowledge of the tumor motion 
and adjustment of the radiation delivery to compensate for such motion will permit a reduction in 
the target volume and, therefore, doses to surrounding normal tissues.  
Potential techniques for incorporating intrafractional respiratory motion into treatment 
planning/delivery include breath-hold, respiration-gating, and tumor-tracking. Breath-hold 
techniques either actively or passively suspend the patient‟s respiration for short intervals or 
deliver treatment during these intervals (1.7). However, patients with lung tumors may have 
compromised breathing capacity and performing stable, extended breath holds for treatment may 
not be feasible. Respiration-gating techniques periodically turn on the treatment beam when the 
patient‟s breathing parameters fall within a predefined range (such as near full-inhale or full-
exhale phase of respiration) (1.8). Tumor-tracking, or four dimensional, methods propose to 
actively track the tumor with the radiation beam as the tumor moves during the respiratory cycle 
(1.9). Tumor-tracking four-dimensional techniques greatly increase the complexity of the 
treatment delivery. All of these techniques require some form of observation of the respiratory 
motion. Current measurement techniques include infrared external marker tracking, spirometry, 
strain gauges, video visual tracking, and fluoroscopic tracking of implanted fiducial markers.  
The motion of a fiducial marker implanted into or near a tumor gives the best information 
about the motion of the tumor. However, the process of percutaneous or endoscopic implantation 
of fiducial markers is an invasive procedure, and fluoroscopic imaging of an implanted marker 
results in additional dose from the x-ray tube. External motion sensors are safer and non-
invasive, but do not correlate as well to internal tumor motions. For patient use, constant 
 3 
fluoroscopic tracking of an implanted fiducial is replaced by visually tracking the motion of 
external markers, whose motion has been correlated to that of the implanted fiducials. 
This project investigated a free-breathing method of respiration gating using a 
combination of implanted fiducial markers for patient alignment and infrared monitoring of 
external infrared markers for gating the radiation treatment beam. By considering respiratory 
motion and utilizing techniques to deliver radiation via respiratory gating during free breathing, 
the traditional margins for intrafractional tumor motion can be reduced. This project investigated 
the margin reductions possible for a respiratory-gated treatment using a motion phantom as a 
surrogate for actual patient investigations. 
1.2. Definition of Volumes 
International Commission on Radiation Units and Measurements (ICRU) Report 50 
(1.10) sets guidelines for volumes in radiotherapy by defining the gross tumor volume (GTV), 
clinical target volume (CTV), and planning target volume (PTV). The GTV is defined as the 
gross palpable or visible/demonstrable extent and location of the malignant growth. The CTV is 
defined as a tissue volume that contains a GTV and/or subclinical microscopic malignant 
disease. The CTV is based on purely anatomic-topographic and biological considerations without 
regard to the movement of the tissues/patient or technical factors. The PTV is a geometrical 
region defined to select appropriate beam sizes and beam arrangements, taking into consideration 
the net effect of all the possible geometrical variations and uncertainties, in order to ensure that 
the prescribed dose is actually absorbed in the CTV where diseased tissue resides (1.11).  Figure 
1.1 shows the evolution of the target volume from the early ICRU 29 report to the most recent 
ICRU 62 report. 
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Figure 1.1: ICRU guidelines for delineating volumes for radiotherapy 
ICRU Report 62 adds the concept of internal target volume (ITV), which is a region that 
encompasses the CTV with an internal margin (IM). The IM accounts for all movements and 
variations in the CTV size and shape both during treatment (intrafraction) and between treatment 
sessions (interfraction). The ITV is expanded into the PTV by adding a setup margin (SM) about 
the ITV. The SM takes into account uncertainties in the reproducibility of patient setup inherent 
in every treatment session. The major component of the ITV formation is the intrafractional 
movement of the CTV due to respiratory motion (1.11). 
The region between the CTV and PTV includes normal, healthy tissue that receives the 
therapeutic dose. As previously stated, the volume of healthy tissue receiving high doses can be 
closely related to the incidence of adverse side effects, especially in the lungs (1.5). Thus, any 
reduction of the internal margin and setup margin used to construct the PTV would reduce dose 
received by normal tissue. 
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1.3 Definition of Respiration Characteristics 
In order to understand terms used throughout this paper, Figure 1.2 illustrates a sample 
breathing trace. A patient‟s chest wall fall and rises over the course of a respiratory period, as 
shown in the y-axis of Figure 1.2. Each respiratory period can be divided into percentages 
ranging from 0 to 99 percent. Full-inhale is considered to be occurring at 0% phase, while full-
exhale is defined as 50% phase. This nomenclature is adopted from the CT scanner 4D 
reconstruction program. Full-exhale is considered to be 0% of the chest wall amplitude, as this is 
when the chest wall is at that lowest position in the anterior-posterior (AP) direction for a patient 
laying supine on the treatment table. Full-inhale would then be the 100% amplitude position of 
the chest well or patient external motion. For a sinusoidal curve, the phase and amplitude are 
mathematically correlated, but actual patient motion is not sinusoidal.  
Figure 1.2 also shows a pink region of amplitude above a line called the reference gating 
level. The reference gating level is selected to be the level about which a window of either phase 
or amplitude is added, which is called the gating window. The gating window is shown as the red 
line on either side of the reference gating level. For the purposes of the work, the “gating 
window level” will refer to the amplitude level signified by the red line. At this location in time, 
the respiratory trace moves out of the gating window, and the treatment beam is gated off. The 
gating window is expressed as a percentage of the respiratory amplitude from full-exhale (0% 
amplitude) to the gating window level. By increasing the gating window level, the treatment 
beam is enabled for a larger portion of the respiratory cycle.  
When the patient‟s respiratory motion is observed to be within the gating window, the 
beam is enabled for treatment. The bottom section of Figure 1.2 illustrates the beam enabling as 
the respiratory motion of the patient moves into the sample gating window. When the patient 
moves out of the gating window, the beam is disabled and radiation delivery is stopped. The 
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gating window can be increased or decreased, as indicated by the vertical arrows on Figure 1.2, 
which affects the amount of beam-on time in each respiratory period.  
 
Figure 1.2: Respiratory motion example diagram showing a respiration trace of 
the patient‟s external anterior-posterior motion and a sample gating sequence 
centered at the full-exhalation phase.  
As the gating window is decreased, the amount of time the beam is enabled is also 
decreased, the overall treatment time is increased, and the motion of the patient during the 
window is decreased. The target motion during the gating window is referred to as residual 
motion. When selecting the size of the gating window, the amount of residual motion and overall 
gated-treatment time must be considered 
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1.4 Respiratory Gating and Internal Margins 
In order to achieve the greatest benefit from respiratory gating, one must understand the 
relationship between ITV expansion margin (IM) and the width of the gating window used for 
treatment. In order to define an appropriate respiratory margin for a given tumor and treatment, 
the residual motion must be known for a given gating window and target motion amplitude. 
AAPM Task Group 76 (1.12) recommends the following steps for treatment planning: 
1. Account for the distortion of the planning CT due to respiratory motion induced artifacts. 
2. Correlate the internal tumor displacement and phase relationship with respect to with 
external markers used in gating. 
3. Quantify the variation between respiratory cycles both intrafractionally and 
interfractionally and the resulting error in treatment margins. 
4. If a patient-specific tumor-motion measurement is made, the information should be used 
in the CTV-to-PTV margin used for treatment planning. 
This project addressed recommendation #1 by imaging a moving implanted metallic coil and 
comparing the image measurements to known coil length and position. Recommendation #2 was 
addressed by using an implanted marker as a surrogate for the internal patient motion to measure 
the internal tumor motion. Imaging an implanted fiducial allows the internal target motion to be 
correlated to observed external marker motion. Because this project used a respiratory phantom 
with predictable and stable motion, recommendation #3 was not considered. Recommendation 
#4 is prescriptive in recommending that patient-specific motion information be used in treatment 
planning. This project gives recommendations on how to incorporate such motion information.  
1.5 Hypothesis 
The goal of this project was to investigate the relationship between internal target motion, 
gating window widths, and internal margin required to accurately cover the CTV. These 
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relationships were studied using radiochromic EBT film, four-dimensional (time-resolved) 
computer tomography (4DCT) and ExacTrac (BrainLab, Munich, Germany) x-ray imaging 
system. 
The hypothesis of this work was that Novalis ExacTrac gating, combined with 4DCT, 
can be used to limit internal margin expansions to less than 3 mm while maintaining 95% 
prescription dose coverage of the CTV for tumors that are influenced by large (>5 mm) 
respiratory induced motions.  
The specific aims were: 
• Aim 1: Develop an accurate and efficient dosimetry system to measure dose distributions 
of respiratory-gated radiation therapy treatments using radiochromic film.  
• Aim 2: Measure, compare, and evaluate the coil localization accuracy of 4DCT and 
ExacTrac gating for respiratory motion amplitudes greater than 5 mm over a typical 
respiratory period. 
• Aim 3: Measure the spatial distribution of dose to a moving phantom using a variety of 
gating window levels and amplitudes for sinusoidal respiratory motion. 
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2 Aim 1: Develop an Accurate and Efficient Dosimetry System 
to Measure Distributions of Respiratory-Gated Radiation 
Therapy Treatments Using Radiochromic Film 
2.1 Introduction 
Film dosimetry can be performed with both radiographic and radiochromic film. Silver-
halide based radiographic films, such as Kodak EDR and Kodak XV-2, have been the standard 
of clinical dosimetry in the past. Limitations include a high effective Z due to the silver in the 
film, creating a non-water equivalent dosimetric response. Also, radiographic films require 
processing facilities (dark room, processor, etc.) and the chemical development process can 
influence the results of the film measurements. The EDR film has a dynamic range of 10-500 
cGy, which includes doses used for a typical patient fraction. XV-2 film, on the other hand, 
saturates at a lower dose near 80 cGy, and is therefore more suitable for quality assurance 
measurements.  
Radiochromic film has significant advantages over radiographic film for x-ray dosimetry. 
Radiochromic film is self-processing, removing the need for dedicated dark room facilities and 
expensive wet chemical processing. However, early types of radiochromic film, such as MD-55 
had low sensitivity (0-10,000 cGy) and so were suitable to measure only high doses (2.1, 2.2).  
The newest radiochromic film, GafChromic EBT (International Specialty Products, Wayne, NJ), 
is been designed for the measurement of absorbed dose in the range of 1-800 cGy (2.3). 
Radiochromic EBT has also been reported to have minimal photon energy dependence (2.4) and 
radiochromic film in general has been shown to be nearly tissue equivalent (2.5). 
Radiochromic film has been shown to be an excellent tool for two-dimensional film 
dosimetry provided that some precautions and corrections are taken into account (2.6, 2.7, 2.8, 
2.9, 2.10). High spatial resolution, minimal energy dependence, and near tissue equivalence 
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make radiochromic film desirable for our film studies. When using a phantom that requires cut 
film pieces, the ability to handle film in room light greatly simplifies the setup process (EBT film 
is relatively insensitive to fluorescent room lighting). Because EBT is self-developing, the 
measurement variations due to wet chemical processing of radiographic film are eliminated 
(2.11). This may allow for a single film calibration to represent the response of an entire batch of 
film, further simplifying film dosimetry.   
We investigated the film characteristics and processes necessary to measure dose 
distributions for gated radiation delivery to a moving respiratory phantom. Medical grade 
scanners are typically used in clinical settings to analyze radiographic films. However, 
radiochromic film users have suggested that a flatbed document scanner may be sufficient, and 
even possibly superior, to traditional medical scanners (2.12, 2.13). In this aim we also compared 
a widely-used medical grade scanner to a flatbed document scanner suggested in recent literature 
in order to decide which scanning system to use for this project, and for clinical use at Mary Bird 
Perkins Cancer Center. 
2.2 Methods and Materials 
Conflicting literature reports necessitated our own investigations into the properties of 
each scanner when scanning EBT film (2.14, 2.15). The performance of each scanner was 
measured in terms of reproducibility, uniformity, noise, and accuracy. Reproducible methods of 
scanning were developed and verified for each scanner. 
2.2.1 Epson V700 Scanner System 
An Epson Perfection V700 Photo scanner (Seiko Epson Corporation, Nagano, Japan) was 
purchased for testing as our radiochromic EBT film scanner at MBPCC.  It is a flatbed document 
scanner designed for high quality photographic scanning. It can operate in both transmission and 
reflective mode, but for the purposes of medical film scanning, it should be used in the 
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transmission mode. The maximum scan area of the Epson scanner is 8.5” x 11.7”. The standard 
radiochromic film is 8x10”, but larger film sizes are available which would exceed the maximum 
scanner area. Due to the lack of FDA constraints in the manufacturing process of flatbed 
scanners like the Epson, scanner manufacturers can substitute components and firmware without 
notice, possibly resulting in significant changes in scanner characteristics (2.14). 
Both systems have supported commercial software that interfaces with the scanner, but 
MBPCC does not possess software for analyzing films scanned with the Epson. 
This scanner is considered to be a replacement for the discontinued Epson Expression 
1680 scanner which is widely used for radiochromic film dosimetry, as reported in several 
publications (2.6, 2.7, 2.8, 2.9, 2.10, 2.12, 2.13). To date, there are no reports on the use of the 
Epson V700 scanner. The Epson 1680 and V700 both utilize a fluorescent light source with a 
broadband emission spectrum and a linear charge coupled device (CCD) array detector. The 
Epson manufacturer reports the scanner resolution can be set to upwards of 12800 dots per inch 
(dpi), or ~0.00198 mm/pixel; however the resolution for all Epson scans was set at 150 dpi to 
balance resolution with increasing file size and scan time. The Epson scanners can save scanned 
image data in a 48-bit red-green-blue (RGB) tagged image file format (TIFF). The ability to 
extract and analyze the red channel data is an attractive feature of Epson flatbed scanners for 
radiochromic film dosimetry. 
The Epson has capabilities for repeat imaging, red channel extraction, and background 
subtraction. Repeat imaging capability refers to the ability to repeatedly image the same film 
without moving it. With repeat imaging capability, the user can take multiple scans of a film and 
average them in order to reduce noise or uncertainty. Red channel background subtraction refers 
to the fact that with a 48-bit RGB image, the 16-bit red channel can be extracted for dosimetric 
purposes. Red channel extraction is useful for radiochromic film because it responds most to red 
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light, so that the red component of the scanned image has the greatest sensitivity. The flexibility 
of the TIFF format allows the user to manipulate the image more than the Vidar .RV4 format, 
such as scan averaging or pre-irradiation film background subtraction. Background subtraction 
means that the film can be accurately placed in the scanner bed, allowing for a pre-irradiation 
scan of the film to be subtracted from the experimental film after exposure using programs such 
as MATLAB (Math Works, Natick, NJ). Background subtraction is also dependent on the 
positioning reproducibility of the film achievable in the Epson system.  
Initial testing showed the response of the Epson V700 scanner at MBPCC to be similar to 
an Epson 1680 at the LSU Medical Physics office. Currently, the EBT manufacturer includes a 
pamphlet in each box of film that recommends using the Epson 10000XL scanner system, but 
this scanner cost is very high (~$2500). This high cost of the 10000XL scanner offsets the cost 
efficiency of using a flatbed scanner if a user already owns a medical grade film scanner, such as 
the Vidar. The Epson V700 scanner currently retails for less than $1000. Thus, we elected to 
evaluate the Epson V700 as the best flatbed candidate against the Vidar for analyzing 
radiochromic film at MBPCC.  
2.2.2 Vidar Scanner System 
The VXR Dosimetry PRO Advantage Film Digitizer (Vidar Systems Corporation, 
Hendon, Virginia) has a fluorescent white light source with a spectral distribution ranging from 
250 to 750 nm and a linear CCD system for measuring transmitted light. Radiographic film is 
currently being scanned at MBPCC using this scanner with the RIT V5.0 (Radiological Imaging 
Technology, Colorado Springs, CO) software.  The RIT software was used to analyze all of the 
Vidar scans for this project. The Vidar scanner always produced a 16-bit grayscale image using 
the entire spectrum of the scanner light source.  
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The digitizer can scan films up to 14” wide. This larger scan area would be useful for 
scanning an entire sheet of larger EBT film (14x17”), now available from the film‟s 
manufacturer. Film is transported past the measurement apparatus, as opposed to the Epson 
scanner where the light source/detector system moves across a stationary film. The Vidar system 
can measure optical density in the range of 0.01 to 3.65. The physical resolution of Vidar scans 
can vary from 0.356 x 0.356 mm to 0.089 x 0.089 mm.  
The FDA-approved Vidar scanner currently uses the established commercial RIT V5.0 
software available at MBPCC and the scanner characteristics are well documented. RIT V5.0 
currently has a feature that attempts to correct for film non-uniformity using a scanned blank 
film, but we are currently not using this module because it is not readily apparent what 
modifications this software module would perform on the film scans. This scanner currently 
costs over $10,000 including the necessary software for analysis. 
When the film moves through the Vidar scanner, the physical movement of the film does 
not allow for exact duplication of the film to the previous position in the scanner. The Vidar 
scanner can be left on at all times, and includes a forced self-calibrating routine to ensure that the 
light source is sufficiently warmed up and stable.  
2.2.3 Summary of Scanner Characteristics 
Table 2.1 shows a side-by-side comparison of the physical characteristics of the two 
scanner systems. Some advantages of the Epson scanner include the flexibility of file formats, 
the ability to use the red light channel to analyze the film, and the fact the film remains stationary 
on the scanner bed. Some advantages of the Vidar scanner include the built-in self-calibration, 
the larger scan area, and the availability of the RIT software in the clinic to analyze the Vidar-
produced images.  
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Table 2.1: Comparison of vendor-provided characteristics of the Epson vs. Vidar 
scanner. 
Scanner Characteristics Epson V700 red channel Vidar Dosimetry Pro  
      
Resolution 508 - 1.98 um 356, 178, 89 um 
Repeat imaging capability yes no 
Red channel extraction capability yes no 
Background subtraction capability yes no 
FDA approved no yes 
Med. physics technical support no yes 
Commercial software capability FilmQA, not in clinic RIT V5.0, currently in clinic 
Output file format .TIF .JPG .BMP .RV4 (RIT proprietary) 
Light source fluorescent white light fluorescent white light 
Detector array linear CCD array linear CCD array 
Maximum scan area 8.5 x 11.7 " 14 x 17 " 
Color depth 48 bit RGB 16 bit grayscale 
Relative scanner cost < $1000 > $10,000 
 
 Of particular interest is that the Vidar scanner currently costs over $10,000, while the 
Epson scanner retails for less than a tenth of this (<$1000).  
2.2.4 Calibration Film Exposure 
Numerous films were exposed to a range of doses from 11.5 to 512 cGy on a Varian 6/18 
EX linear accelerator using a clinical 8-box radiographic film calibration setup technique. The 
calibration technique involves placing the film perpendicular to a 6 megavoltage (MV) beam at 
100 SAD and 10 cm depth in solid water, with 10 cm of solid water below the film for sufficient 
backscatter conditions. Radiation is delivered using predefined multileaf collimator sequence 
that creates two columns of four separate rows of 3x3 cm
2
 regions on the film. Each region 
received a different known dose. An ion chamber was previously used to measure the dose under 
each of the eight dosed regions on the film as well as a low dose region receiving indirect scatter 
contribution in the center of the film. These measurements of each region account for not only 
dose directly from delivered to each field, but leakage and scatter contributions from the other 
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seven delivered fields. Figure 2.1 shows the eight visible dose regions labeled 1-8, and a region 
of scattered low dose labeled as region 0.  Dose regions 0-8, as indicated in Figure 2.1, receive 
doses of 11.5, 67.3, 137.8, 199.8, 259.2, 320.4, 392.6, 453.8, and 511.9 cGy, respectively. These 
doses cover most of the manufacturer-specified dynamic range for EBT film (0-800 cGy).  
 
 
Figure 2.1: Radiochromic EBT film irradiated under MBPCC calibration 
conditions showing the nine dose regions and corresponding doses measured for 
film analysis 
All films were irradiated under the same conditions, at the same time, and unless 
otherwise specified, were from the same batch of film. Film exposure to room lighting was 
minimized and relatively equal, thus neglected when comparing similar films. The films were 
labeled and stored back in the film box for a period of 24 hours before scanning. This was to 
ensure that all polymer changes within the film due to the irradiation had completed. All films 
were stored together before and after irradiation to keep all film thermal history the same. No 
special consideration was given to regulating the film environment beyond the room temperature 
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and humidity conditions maintained by the facility‟s air conditioner. Films were stored in opaque 
film protectors before and after readout to minimize room light exposure. 
2.2.5 Film Scanning Procedures 
The experiment films (8x10”) were smaller than the maximum scanner bed size for both 
scanners. Therefore, experiment films were placed in the center region of each scanner for 
scanning. Pixel size in both scanners was chosen to be similar: 178 µm for the Vidar scanner and 
169 µm (150 dots/inch) for the Epson scanner. This was done in order to balance a small pixel 
size with an increasing scan time and overall size of the image files generated. Unless otherwise 
stated, all films were scanned 24 hours post-irradiation to allow sufficient time for all self-
development to complete within the experimental film.  
For all Vidar scans, the self-calibration process was completed at the start of every film 
scanning session. The Vidar light source requires the user to allow the light source to “warm-up” 
and stabilize before scanning any films. Also, before every film is scanned, the Vidar 
automatically repeats a shorter routine to ensure the light source is still sufficiently stable. After 
calibration completed, the film was placed by hand into the center of the scanner, and the RIT 
software completed the scanning process.  The RIT software was used for all subsequent film 
analysis and measurement of Vidar-produced images.  
The EBT manufacturer recommends and will provide a clear polyester sleeve to secure 
film pieces for transport through the Vidar system. We found these sleeves to be unacceptable 
due to circular Newton ring artifacts caused by reflecting interference at different thicknesses of 
the air layer between the sleeve surfaces. These rings were clearly visible to the eye and on the 
resulting scans in the Vidar scanner. We consider the use of such sleeves unsuitable for our film 
dosimetry system. 
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For all Epson scans, only the red channel data was analyzed for this project. All image 
enhancement features were turned off in the EpsonScan program. No background subtraction, 
uniformity correction, or other processing was used on these scans unless noted. The Epson 
scanner always created a 48-bit RGB file, but the 16-bit red channel was extracted and analyzed 
for all reported measurements. The ImageJ software package was used to analyze the pixel 
values for the 16-bit red channel images. ImageJ is a java-based image processing software 
program developed at the National Institutes of Health. ImageJ is capable of analyzing TIFF 
format images, and measuring mean and standard deviation values for selected regions of 
interest. ImageJ does not have the capabilities to perform film calibration or treatment planning 
import and comparison. Because no calibrated commercial step wedge is known to exist for 
radiochromic film, no conversions from pixel value (PV) to optical density were performed 
unless noted. All data are reported in terms of pixel values. 
Paelinck, et al. recommends not using the first three scans from the 1680 model Epson 
scanner when beginning a new film scanning session (2.9). Epson scanners have no built in 
procedure to “warm-up” the light source before scanning. The user must simply acquire 
numerous unusable scans until the user feels the light source is sufficiently stable. For the 
purposes of this study, at least 30 minutes were allowed after turning on the Epson scanner 
before scanning, and at least 10 Epson scans without film in the scanner were taken before data 
collection. Paelinck reported on the warm-up characteristics, or short term drift, of the 1680 
model Epson (2.9) but no one has reported on the short or long term stability of the V700 Epson 
model. The user cannot be sure when or if the Epson scanner light source is sufficiently 
stabilized, which is a major disadvantage with the Epson scanner.  
For the Epson scanner, RIT 4.4 software was used during initial analysis of the TIFF 
images. A MATLAB routine was written in order to convert the Epson produced TIFF images 
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into a DICOM (Digital Imaging and Communications in Medicine) format which was acceptable 
for importation in the RIT software. In RIT V5.0, however, the software would no longer allow 
the DICOM files created from TIFF images to be calibrated, effectively prohibiting the use of the 
RIT software with the Epson scanner with this approach.  
For reporting results, sometimes presenting the data in terms of optical density instead of 
PV may be more informative for the observer. It should be noted that the pixel value is actually 
the value returned by the scanner system‟s analog-to-digital converter, and is generally system 
dependant. Typically for radiographic film dosimetry in the RIT software system, a calibrated 
optical density step wedge is scanned into the system. The RIT software finds a mean PV over 
the central portions of each step and creates a curve relating the pixel value to optical density. 
This correlation is used to convert the pixel values measured by the RIT software system into 
optical density values. Because no calibrated step wedge exists for radiochromic film, measured 
pixel values cannot be converted into optical density. Therefore, when optical density is reported, 
it was calculated manually using the definition of optical density: 
    ,     eq. 1 
where I equals the intensity of the transmitted light beam, and I0 is the intensity of the incident 
light beam on the film. For a 16-bit gray-scale or red-scale image, I was taken as the reported 
pixel value and the incident beam, I0, was assumed to have a pixel value of 65535 (2
16
-1). 
Unfortunately, the accuracies of the Epson and Vidar scanners cannot be assessed by comparison 
to a manual point densitometer because the light spectra are different and the transmission of 
radiochromic film is wavelength dependant. To avoid confusions about optical density, most data 
are presented in terms of unique raw pixel values that are reported by the scanner systems. 
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2.2.6 Film Testing 
Unless otherwise noted, for each film test, we report the mean of the central 1.5x1.5 cm
2
 
area of each dose region as the “film response” of that particular dose for the nine dose levels 
observed on each experimental film. For the region of low dose, a 1.5x1.5 cm
2 
area was chosen 
in the center of the film to represent region 0. Regions 1-8 are as defined in Figure 2.1. All films 
were scanned 24 hours post-irradiation.  
2.2.6.1 Scanner Constancy 
To test the repeatability of each scanner, a single calibration film was scanned 10 times in 
rapid succession on each system. The RIT software was used to measure the film response of 
each dose region. For all nine dose regions, the film response was calculated and the standard 
deviation of the ten scan measurements was computed. 
2.2.6.2 Film-to-Film Variation 
To test film-to-film variations, five calibration films from a single batch were irradiated 
at the same time. Each film was assumed to have received the same dose in each of the 
corresponding dose regions. The average film response for each dose level was recorded for each 
film and standard deviation of the five measured film responses was calculated.   
2.2.6.3 Batch-to-Batch Variation 
Manufacturing conditions may vary among different production batches. In order to study 
this effect, one film from each of three separate batches of EBT film was selected. The three 
films were irradiated under calibration conditions and analyzed at the same time. Table 2.2 
provides the basic information on the three batches tested.  Batches 1 and 2 came from film 
batches purchased and stored at MBPCC; batch 3 is a sheet from a batch at Louisiana State 
University used in previous film studies.   
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Each film was scanned three times in the Vidar system. The three measured film 
responses for each film were averaged for each of the nine dose regions. The percent differences 
of the film response of Batches 2 and 3 from Batch 1 were calculated. Batch 1 was selected as 
the comparison standard because the all other tests in this aim use films taken from Batch 1.  
Table 2.2: Batch numbers for films compared in this study 
Name Lot Exp Date Location 
Batch 1 35322-0021 Nov-07 MBPCC 
Batch 2 36348-041 Dec-08 MBPCC 
Batch 3 35322-0041 Nov-07 LSU 
 
2.2.6.4 Film Orientation Effects 
 The optical density of EBT film may change substantially depending on the polarization 
of the analyzing scanner light relative to the orientation of the film. This effect has been 
attributed to the alignment of the radiochromic film polymer chains which form after irradiation 
(2.16). Zeidan et al. reported measurement of an effect with a 90 degree rotation of the film in 
the scanner where the measured optical density dropped by 50% for 50 cGy to 25% for 200 cGy 
(2.17).  Because the scanners have different light source spectra and detector properties, it was 
necessary to measure film orientation effect in both scanning system 
A single calibration film was scanned in both portrait and landscape orientations. The 
film responses of all dose regions in the portrait orientation were compared to the landscape 
orientation in terms of percent difference. Portrait orientation was defined as the long axis of the 
film being perpendicular to the linear scanner light source; landscape orientation was defined as 
the long axis of the film being parallel to the linear scanner light source. Although film scanning 
at any orientation is possible in the Epson scanner, only portrait and landscape orientations are 
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possible with the Vidar scanner. The bank of film rollers in the Vidar scanner require a straight, 
even film edge to grab.  
2.2.6.5 Scanner Light Effect 
EBT film has a small response to light and, therefore, the scanning process itself could 
affect results. To characterize the effect, a calibration film was scanned 30 times and the change 
in film response measured after every 10 scans over a span of several days. Only the Vidar 
scanner was used for this test, but the Epson scanner has a similar fluorescent white light source, 
which would affect the film in the same manner.  
The film was scanned 10 times in rapid succession 24 hours after irradiation. The initial 
average of the 10 measured film responses gave a baseline reading for each dose. After another 
period of 24 hours, the film was scanned again 10 times again in rapid succession. This 
measurement of the film response compared to the baseline response measured the effect of the 
light from the initial 10 scans. This process was repeated a third time after another 24 hours to 
quantify the effect of the 20 previous scans. Finally, after another 24 hour period, the film was 
scanned again to measure the effect of 30 scans of the film.  Waiting 24 hours between scanning 
sessions allows any scanner light effects from the previous day to completely polymerize within 
the film.  
2.2.6.6 Scanner Uniformity 
A single piece of blank, non-irradiated radiochromic film was scanned in portrait 
orientation using both systems. Horizontal and vertical profiles were taken through center of 
each film, and the resulting PV profiles were compared. This test assumed that the film was of 
uniform optical density over the entire sheet. The horizontal profile is indicative of how uniform 
the detectors are across the width of the central scanner bed in each system. The vertical profile 
is recorded by the same light/detector segment as the scanner operates. Thus, a vertical profile of 
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a blank film should show how uniform the same detector segment is over the course of scanning 
a film.  
2.2.6.7 Measurement Noise 
A single calibration film was used to test the overall measurement noise. The central 
1.5x1.5 cm
2 
portion of each dose region was assumed to be uniform. The measurement noise of 
the scanner/film system was taken to be the measured standard deviation of all the pixels in the 
central 1.5x1.5 cm
2
 of each dose region. This measurement was performed for both scanners. 
This noise measurement includes scanner, film, and irradiation variations, and gives an estimate 
of the precision of the film response measurement.  
2.3 Results 
2.3.1 Scanner Constancy 
The scanner constancy results of both systems are shown in Table 2.3. The table shows 
the average of the ten measured film responses (μ), the standard deviation (σ) of the 
measurements, and the standard deviation expressed as a percentage of the film response (μ/σ) at 
each dose. Each scanning system reported a different film response due to hardware differences 
and, especially, the use of the Epson red channel versus the white light of the Vidar scanner.  
The largest standard deviation of the film response can be seen as 0.22% at 199.8 cGy for 
the Vidar, and 0.17% at 67.3 and 137.8 cGy for the Epson scanner. The maximum standard 
deviation for either scanner was less than 0.22% of the measured film response over the dose 
range tested.  
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Table 2.3: Film response and standard deviation of the film response over 10 
repeated scans on a single calibration film.  
  Vidar   Epson 
Dose (cGy)   μ σ σ/μ   μ σ σ/μ 
11.5   45280 46 0.10%   47581 61 0.13% 
67.3   36053 73 0.20%   37783 65 0.17% 
137.8   29710 52 0.17%   31297 53 0.17% 
199.8   25592 56 0.22%   27132 41 0.15% 
259.2   22726 42 0.18%   24350 29 0.12% 
320.4   20783 31 0.15%   21762 35 0.16% 
392.6   18883 20 0.11%   19918 27 0.14% 
453.8   17433 20 0.11%   18562 23 0.12% 
511.9   16276 18 0.11%   17490 13 0.07% 
 
2.3.2 Film-to-Film Variation 
Table 2.4 shows the film response pixel values for all dose regions as measured with the 
Vidar system for the five different films scanned. The film responses of all dose regions are 
reported for all five films labeled A-E. The average film response of all five experiment films 
(μ), standard deviation (σ) and standard deviation reported as a percentage of the mean (σ/μ) are 
also reported in Table 2.4. No more than 0.39% standard deviation is observed between different 
films of the same batch irradiated under identical conditions and given identical time (24 hours) 
to self-develop.  
Table 2.5 shows data for the same five films as analyzed in the Epson scanner. The 
maximum standard deviation is 0.51%, only slightly larger than for the Vidar scanner. Figure 2.2 
shows a Hurter–Driffield (HD) curve showing the optical density calculated using equation 1 
from the pixel values as given in Table 2.4. Since HD curves are commonly displayed in terms 
of optical density, not pixel value, the calculated optical density was used for plotting purposes. 
For all five films, the resulting HD curves are nearly indistinguishable from each other. 
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Table 2.4: Film-to-film variation in film response as measured with the Vidar 
scanner system 
Dose 
(cGy)    Film A Film B Film C Film D Film E  μ  σ σ/μ  
11.5   45690 45665 45719 45625 45760  45692 51 0.11% 
67.3   36777 36582 36758 36448 36736  36660 142 0.39% 
137.8   30272 30263 30282 30182 30387  30277 73 0.24% 
199.8   26124 26098 26171 26067 26157  26123 42 0.16% 
259.2   23340 23267 23267 23176 23276  23265 58 0.25% 
320.4   21155 21078 21038 21096 21056  21085 45 0.21% 
392.6   19095 19136 19125 19185 19288  19166 76 0.39% 
453.8   17699 17718 17723 17674 17733  17709 23 0.13% 
511.9   16470 16490 16469 16535 16526  16498 31 0.19% 
 
Table 2.5: Film-to-film variation in film response as measured with the Epson 
scanner system 
Dose (cGy)   Film A Film B Film C Film D Film E   μ σ σ/μ  
11.5   46471 46538 46438 46320 46472   46448 80 0.17% 
67.3   37482 37667 37696 37444 37279   37514 172 0.46% 
137.8   31224 31238 31342 31217 31126   31229 77 0.25% 
199.8   26962 26958 27146 27008 26970   27009 79 0.29% 
259.2   24120 24171 24283 24245 24208   24205 63 0.26% 
320.4   21870 22053 22014 21967 21780   21937 111 0.51% 
392.6   20157 20162 20209 20121 19987   20127 84 0.42% 
453.8   18562 18722 18636 18582 18494   18599 85 0.46% 
511.9   17489 17532 17493 17424 17344   17456 74 0.42% 
 
Thus, films from the same batch, given the same irradiation conditions and allowed to 
self-develop by the same amount of time, will be very uniform in response. From this we 
conclude that a single calibration would be sufficient for each batch of film.  
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Figure 2.2: Hurter-Driffield curve for the five calibration films scanned with the 
Vidar system 
2.3.3 Batch-to-Batch Variation 
For an inter-comparison between batches of radiochromic film, calibration films from 
each of three different batches were analyzed using the Vidar scanner. Table 2.6 shows the 
average film response (μ) for three repeated scans of each dose region on the film from each 
batch.  
Film from Batch 1 was used for all the other testing in this aim. The last two columns of 
Table 2.6 show the percent difference for each dose region of batches 2 and 3 with respect to 
batch 1. The equation used to calculate the percent difference from batch 1 was:  
     ,    eq. 2 
where µ1 and µx are the mean values of corresponding dose regions between batches 1 (µ1) and 
batches 2 or 3 ( ). The batch-to-batch variation is large when compared to the film-to-film 
variation. Batch 2 differs from batch 1 by up to -9.30% in the high dose regions, while batch 3 
differs by 8.52% in the region of the film receiving low dose. In the regions 1-8, batch 3 differs 
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from batch 1 by less than 3.45% percent difference for all dose regions. Figure 2.3 shows the HD 
curve from the three films from different batches. The optical density values were calculated 
using equation 1.  
Table 2.6: Comparison of calibrated films taken from three different batches. The 
average film response (μ) is listed with the percent difference of the film 
responses of batches 2 and 3 from batch 1.  
 Dose (cGy)  
Batch 1 
μ  
Batch 2 
μ  
Batch 3 
μ 
  
  
Batch 2 
% Diff 
Batch 3 
% Diff 
11.5 45336 48214 49198   6.35% 8.52% 
67.3 36637 36817 37901   0.49% 3.45% 
137.8 30218 29514 30866   -2.33% 2.15% 
199.8 25959 24886 26084   -4.13% 0.48% 
259.2 23105 21870 23276   -5.34% 0.74% 
320.4 21234 19671 20872   -7.36% -1.71% 
392.6 19239 17795 18936   -7.51% -1.57% 
453.8 17560 16314 17294   -7.10% -1.51% 
511.9 16653 15105 16195   -9.30% -2.75% 
 
On each box of EBT film, a nine digit number is posted to identify the lot and batch 
number of the film within the box. It is interesting to note from Table 2.2 that the batches 1 and 3 
have the same first five digits, and the same expiration date. Batch 2 was manufactured some 
time after batches 1 and 3 as evidenced by the expiration date on the box. For film batches 1 and 
3, which were manufactured near the same time, the percent difference is less than the difference 
between batches 1 and 2. This would suggest that either slight changes to the manufacturing 
process or the overall age of the film have changed the film‟s response slightly.  
For films from different batches, up to a 9.3% difference in film response was observed.  
While this is not as pronounced of an effect as previously observed in radiographic films, it is 
still a considerable difference. Therefore, care must be taken to generate a calibration for each 
batch of film.  
 28 
 
Figure 2.3: HD Curve for three batches of film as measured using the Vidar 
scanner.  
2.3.4 Film Orientation Effects 
The effects of film orientation are reported in Table 2.7. For each scanner system, the 
first column shows the measured PVs of a single film scanned in portrait orientation. The 
measured values in landscape orientation are given in the second column labeled “Land”. The 
third column shows the percent difference between the portrait and landscape orientations. The 
percent difference of the two orientations was defined as 
    ,   eq. 3 
where  is the mean PV in the landscape orientation while  is the mean PV in the 
portrait orientation. 
As seen in the table, the measured pixel values showed a change between the two film 
orientations. The Epson scanner showed a larger variation between the two orientations, 
registering 17.40% percent difference between the portrait and landscape mean pixel values at 
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the 453.8 cGy dose region. The largest deviation observed by the Vidar was 5.27% at 392.6 cGy 
dose region. Thus, the Epson is more susceptible than the Vidar to orientation effects. The larger 
susceptibility of the Epson to orientation effects may be due to the Epson scanner‟s use of red 
light, which coincides with the absorption peak of the film, as opposed to the Vidar which 
observes the entire spectra emitted by the scanner lamp.  
 
Table 2.7: Measurement of the effect of film orientation during scanning 
 Epson   Vidar 
Dose (cGy) Portrait Land % Diff  Portrait Land % Diff 
11.5 47344 50132 5.89%   48052 48584 1.11% 
67.3 37382 40716 8.92%   36617 36868 0.69% 
137.8  30976 34501 11.38%   29265 29968 2.40% 
199.8  26620 30092 13.04%   24422 25157 3.01% 
259.2  23945 27012 12.81%   21526 22068 2.52% 
320.4  21504 24901 15.80%   19419 20243 4.24% 
392.6  19660 22966 16.82%   17431 18350 5.27% 
453.8  18057 21199 17.40%   15820 16595 4.90% 
511.9  17027 19806 16.32%   14638 15283 4.41% 
 
2.3.5 Scanner Light Effect 
Table 2.8 shows the effect of scanning on film darkening. It was assumed that over the 10 
repeated scans on each day, that the scanner and room light would have negligible effects during 
the scans. Therefore, each day the scanner is measuring the additional darkening effects of the 
ten scans from the previous day. When the film was kept away from room light for 24 hours then 
rescanned, any additional darkening of the film is attributed to the effects of the room/scanner 
light on the film.  
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The original irradiation was considered to occur on Day 0. After 24 hours, on Day 1, all 
of the self development is complete from the initial irradiation. The Day 1 column shows the 
mean film response of ten scans that measured the effect of the radiation alone. On Day 2, the 10 
scans measured the additional darkening caused by the scanning on Day 1. Similarly, each 
successive day‟s reading measured the increased darkening caused by the scanning of the 
previous day. For the scans conducted on Day 4, the measured pixel values included 30 scans 
worth of light exposure from the scanner. The percentage change from the original value, or 
percent error, of each day as compared to the original readings on Day 1 is given in the three 
columns to the right. The equation used to calculate the percent error is: 
     ,   eq. 4 
where μi is the average film response after a certain number of scans, and μinitial is the baseline 
film response.  
Exposure to light should some cause film darkening and corresponding decreases in pixel 
value. Thus, the percent differences should be negative, as seen in Table 2.8, and also become 
larger in magnitude as the light from more scans affect the film. On average over all nine dose 
regions, a 1.56% decrease in pixel value was measured after 30 scans are taken of the film. The 
largest decrease in pixel value after 30 scans was less than 2% observed at 259.2 cGy. For 
clinical measurements, the film would be scanned no more than a few times. Thus, the effect of 
the scanner light should be a negligible. Even if a single film was used for calibration per batch, 
there are only 25 sheet of film per box. Thus, even if a single calibration film were used per box, 
and scanned each time a single film measurement was taken every day, the calibration film 
would be scanned 24 times at most, introducing an error due to additional scanner light <2%. 
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Table 2.8: Effect of the Vidar scanner light on EBT film for film irradiated on 
Day 0. On each day, the average film response over ten scans performed on that 
day is reported.  
 Day 1 Day 2 Day 3 Day 4  % Change from Initial 
Dose (cGy) Initial 10 Scans 20 Scans 30 Scans 
 
10 Scans 20 Scans 30 Scans 
11.5 45538 45279 45232 45235  -0.57% -0.67% -0.67% 
67.3 36301 36052 35972 35880  -0.69% -0.91% -1.16% 
137.8 30020 29710 29573 29561  -1.03% -1.49% -1.53% 
199.8 25878 25591 25520 25460  -1.11% -1.38% -1.61% 
259.2 23030 22726 22633 22578  -1.32% -1.73% -1.96% 
320.4 20990 20783 20671 20615  -0.99% -1.52% -1.79% 
392.6 19080 18882 18789 18741  -1.03% -1.52% -1.78% 
453.8 17613 17433 17357 17327  -1.03% -1.46% -1.62% 
511.9 16446 16275 16182 16135  -1.04% -1.61% -1.89% 
 
 The average darkening of a film exposed to 10 scans was less than one percent. 
Therefore, on average, for the first ten scans of a film each scan should only decrease the pixel 
value by 0.1% if given 24 hours to complete any further self-development. This measurement 
shows that the effect of the scanner light is negligible; even when the film is given ample time to 
further self-develop from any scanner light exposure and limited handling in room light during 
scans.  
2.3.6 Scanner Uniformity 
Uniformity of scanner response was measured by scanning the central axis of a blank 
film along both the vertical and horizontal axes. Figures 2.4 and 2.5 show profile comparisons of 
the Vidar and Epson scanners in the vertical and horizontal axes, respectively.  
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As seen in the figures, the Vidar scanner registers higher pixel values for the blank film 
than does the Epson scanner. This is due to differences in the analog-to-digital converters, and 
the fact the Epson profile is taken from the red light channel. Important non-uniformities are seen 
in the first and last inch of the Vidar vertical profile that are not observed in the Epson vertical 
scan. This can be attributed to the Vidar film transport mechanism, as reported by Wilcox, et al. 
(2.15). 
Ignoring the leading and trailing inches of film, the Vidar vertical profile has a mean 
value of 50653 and a standard deviation of 174 or 0.34% of the mean. The Epson scanner 
vertical profile has a mean value of 49060 and a standard deviation of 160, or 0.33% of the 
mean. Thus, when the roller artifacts are ignored in the Vidar system, both systems have similar 
horizontal response uniformity.  In the horizontal direction, no artifacts are noted in either 
system. The Vidar scanner registers a mean value of 50464 and a standard deviation of 353, or 
0.70% of the mean, over the horizontal profile of the blank film. The Epson scanner gives a 
similar result with a mean of 48646 and a standard deviation of 298, or 0.61% of the mean. Both 
systems show small systematic errors that probably account for the increased non-uniformity. 
In the vertical profile, the measurement shows the response of a single detector along the 
film. If we consider this detector to be stable, the variation measured in the vertical profile gives 
us a measure of the variation across the film. This variation is smaller than the variation as seen 
over the horizontal profile which shows the response of all the detectors across the film at a 
single instance of time. The horizontal profile gives us a measure of the variation across not only 
the film, but across all of the detectors that the film passed through during measurement.  
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Figure 2.4: Vertical profiles of a blank film as measured by the Vidar and Epson 
scanner systems 
 
 
Figure 2.5: Horizontal profiles of a blank film as measured by the Vidar and 
Epson scanner systems 
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2.3.7 Measurement Noise 
Table 2.9 shows, for each scanner, the measurement noise at each dose level. For each 
dose level, transmission values were measured at all pixels in a 1.5x1.5 cm
2
 area. The standard 
deviation of those values is interpreted to be the overall measurement noise, and includes 
scanner, film, and irradiation variations. The table gives the mean pixel value (PV), the standard 
deviation (σ), and standard deviation expressed as a percentage of the mean (σ/PV).  
The absolute standard deviation at each dose was approximately the same for both 
systems, but because the Vidar registered slightly lower mean pixel values, the standard 
deviation expressed as a percent of the mean was slightly higher. For both systems, the 
measurement noise was less than 1.15% for all doses. The largest observed noise occurred in 
both systems at the 453 cGy dose level. For doses less than 400 cGy, scanner noise was less than 
one percent in both scanner systems. 
Table 2.9: Measurement of the noise from the Vidar and Epson scanner systems 
  Vidar Epson 
Dose (cGy) PV σ σ/PV PV σ σ/PV 
0 50709 157 0.31% 49061 145 0.29% 
11.5 47800 187 0.39% 46838 172 0.37% 
67.3 36742 186 0.51% 37469 166 0.44% 
137.8 29435 180 0.61% 30932 151 0.49% 
199.8 24895 175 0.70% 26646 180 0.68% 
259.2 21995 171 0.78% 23875 172 0.72% 
320.4 19727 168 0.85% 21819 141 0.65% 
392.6 17658 170 0.96% 20106 161 0.80% 
453.8 16192 185 1.14% 18655 186 1.00% 
511.9 15074 163 1.08% 17550 144 0.82% 
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2.4 Conclusions 
 We found that film-to-film variations within a single batch were very low with standard 
deviations of less than 0.39% for the Vidar scanner and less than 0.51% for the Epson scanner. 
However, batch-to-batch variations were significant, up to 9.3% in one case. We conclude that 
for a single batch of film, a single calibration is adequate for all experimental films in that batch, 
but that each batch of film must be individually calibrated.  
 Both scanners showed nearly the same performance in terms of measurement 
repeatability, uniformity, and overall measurement noise. Surprisingly, the cheaper, commercial 
flat bed scanner even slightly out-performed the medical grade Vidar scanner in a few categories 
such as scanner noise and scanner uniformity.  
If the film has been cut into squares, the original orientation of the film from which the 
piece was cut should be clearly marked. It is clear that in it is not acceptable to rotate the film by 
90 degrees in either scanner. Care must be taken when using radiochromic film in order to 
maintain the same orientation of the film from calibration to analysis of experimental films. For 
all subsequent film studies in this project, the portrait orientation of the film was maintained in 
all scans. 
No corrections were used to correct for any non-uniformity in the detector response. This 
is due to the low variation of <0.70% SD from the mean over the horizontal profile of a blank 
film as measured in both scanners.  
One significant problem in using the Epson scanner is the lack of support by the Epson 
Corporation for radiochromic film applications. Users of Epson scanners for medical film 
analysis constitute a tiny fraction of Epson scanner users, and that is unlikely to change in the 
future. Customer support, technical specifications, and software development are all geared to 
the majority of the scanner‟s customer base. With the large customer base of Epson scanner not 
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conducting medical grade film scanning, it is unlikely that much help in these categories will be 
provided to the tiny segment of users interested in radiochromic film scanning. Due to the lack of 
FDA constraints in the manufacturing process, graphic arts scanner manufacturers like Epson 
can substitute components and firmware without notice, possibly resulting in significant 
differences between scanners (2.14) 
Another significant issue with the Epson scanner is the fact that no self-calibration of 
light source or warm-up tests exist. The user must simply take many preview scans with the 
Epson scanner and assume the scanner is adequately warmed up. In this testing, no drift was 
observed during repeated film scanning, but there is no guarantee that the Epson light source is 
sufficiently warmed up.  
In contrast to the Epson scanner, the Vidar scanner has a forced self-calibrating routine at 
the start of every run of film analysis. However, an issue did arise with the Vidar scanner on the 
leading and trailing edges of a scanned film. This has been reported by Wilcox, et al. (2.15) and 
was confirmed in our testing. The leading and trailing edge of the film profile perpendicular to 
the light source measured a 3% increase in pixel value. The artifacts can be avoided by ignoring 
the leading and trailing inch of film in a film scan, or by affixing a piece of film to a larger film 
guide for transportation through the Vidar scanner. 
The EBT manufacturer‟s recommendation of using polyester sleeves with the Vidar 
scanner was determined to be unacceptable due to artifacts caused by light reflection from the air 
between the sleeves. For all subsequent film investigations with cut film pieces, film was 
scanned by affixing the cut film edges to a larger film for transportation past the measurement 
slit in the Vidar scanner, and will be discussed later. 
Both film scanners proved to be reliable and accurate for film dosimetry. Therefore, the 
next concern was the ease of use and availability of the scanner software. In our clinic, the lack 
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of commercially available software for using the Epson scanner was a major disadvantage. The 
commercial RIT 5.0 software system has proven useful enough to warrant not developing or 
purchasing software for using the Epson scanner. If an institution already has a working Vidar 
scanner system, we cannot see a clear reason to adopt an Epson scanner system. If an institution 
does not have a medical film scanner similar to Vidar, the Epson scanner may be an attractive 
alternate to purchasing a Vidar scanner just for radiochromic film dosimetry.  
Because our clinic already has the RIT software on site and all the tools and experience 
necessary for film dosimetry with the Vidar scanner, it was decided to use the Vidar system and 
RIT software for the remainder of this research.  
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3 Aim 2: Measure, Compare, and Evaluate the Coil Localization 
Accuracy of 4DCT and ExacTrac Gating for Respiratory 
Motion Amplitudes Greater than 5 mm over a Typical 
Respiratory Period. 
 
3.1 Introduction 
 This aim will track an implantable coil imbedded into the Quasar phantom to determine 
the coil localization accuracy of both the ExacTrac (ET) and the 4DCT system. The ability of 
each system to track the moving implanted fiducial provides data on how well each system can 
track a moving tumor. Should a coil be implanted into a patient, it is necessary to know the 
accuracy of each system to resolve and track the coil over all phases of respiration.  
3.1.1 The Quasar Respiratory Phantom 
The Quasar respiratory motion phantom (Modus Medical Devices, Ontario, Canada) is a 
device which simulates one-dimensional patient respiratory motion. A cylindrical canister moves 
horizontally in the superior-inferior direction to simulate internal lung motion, while a platform 
moves vertically (anterior-posterior) to simulate the patient‟s external chest wall motion. The 
phantom produces one-dimensional sinusoidal motion with the canister and platform driven by a 
rotating ovoid cam. The chest wall platform amplitude is fixed at 10 mm, while the canister 
amplitude can be manually adjusted from 0 to 50 mm motion amplitude. Figure 3.1 shows the 
Quasar phantom setup on the Novalis treatment table. 
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Figure 3.1: The Quasar Respiratory Motion phantom on the Novalis treatment 
couch and five reflective BrainLab bodymarkers used by the ExacTrac system to 
monitor the external chest wall/platform motion 
3.1.2 Implanted Markers 
 Due to the lack of radiographic contrast in tissues such as lung, surrogates are commonly 
used to measure internal tumor motion. The chest wall and diaphragm are commonly used 
motion surrogates, and their motions are strongly correlated (3.1). The diaphragm motion may 
correlate well with the vertical motion of the abdomen, but lung is a non-rigid tissue that may 
move and deform differently (3.2). To accurately track an internal tumor, an implanted fiducial 
marker gives more accurate information than just external patient monitoring.  
To properly gate a treatment beam using external patient markers, the internal patient 
respiratory motion must be correlated with the external chest wall motion observed by the gating 
system. Ionascu et al. report that some patients should not be treated using only external markers 
as surrogates for internal motion (3.3). This is due to an occasionally observed phase shift in the 
external and internal motion correlation of some patients. Some systems, such as the Varian 
RPM gating system, utilize a method of tracking external markers to gate the treatment beam 
without correlation to the position of the internal target (3.4). One way of gating without using an 
external surrogate as a monitor of the patient‟s internal movement involves fluoroscopic tracking 
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of the target, but this can result in unnecessary patient dose and may suffer from low target 
contrast with the surrounding tissues.  
An implanted fiducial marker, such as a metallic coil, is desirable for imaging using the 
ExacTrac kV x-ray system to provide better contrast with surrounding patient anatomy, and 
better correlation to the tumor motion than using solely external markers. After the coil is 
implanted, the relation between the coil location and the tumor or target location can be verified 
using 4DCT. If the coil is placed close enough to the tumor, then the coil can provide an 
excellent internal surrogate to image instead of the tumor because some tumors (e.g. lung or 
liver) may be difficult to detect on x-ray images. Willoughby et al. have shown that the fiducial 
coil implants into lung tissue did not migrate over the course of their study (3.5). Nelson et al. 
reported that smaller implanted spherical and cylindrical markers either dislodged completely or 
remained in place throughout their study (3.2). The study by Yan et al. concluded the ExacTrac 
implanted marker registration and setup showed a higher degree of accuracy over the using an 
anatomical image fusion method (3.6).  
By utilizing the x-ray system to image the implanted coil, the user can ensure the internal 
target is at the planned treatment position using the relation of the implanted coil to the tumor 
location. The ET imaging system allows for a correlation of external infrared-reflecting markers 
(Bodymarkers) to internal target position as defined in relation to the implanted coil.  
3.1.3 4DCT Acquisition 
By determining the most accurate and stable 4DCT respiratory dataset, this project can 
recommend which breathing phase to use as the reference breathing phase, about which the beam 
is gated within a predefined phase window. This project anticipates this to be the full-exhale 
(50%) phase of respiration. Studies have shown that the exhale phases of respiration last longer 
than the inhalation phases of respiration, thus a patient spends more time at exhale than at inhale 
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(3.1, 3.7). Exhalation is reported in these studies to be the most stable and reproducible position 
for patients. 
4DCT data are acquired at MBPCC using the GE Advantage 4DCT v1.6 software on a 
GE Lightspeed RT multi-slice scanner (General Electric Company, Waukesha, WI). The Varian 
Real-Time Positioning Management (RPM) System (Varian Oncology Systems, Palo Alto, CA) 
is used as the external monitoring device. The patient‟s abdominal motion is monitored by the 
RPM camera system shown in Figure 3.2. An infrared (IR) camera mounted at the foot of the CT 
couch emits IR light that is reflected back to the camera via two markers on a plastic box affixed 
inferior to the patient‟s xyphoid process. As the patient breathes the RPM marker box moves 
with the chest wall motion. The time-dependant motion of the box is recorded by the camera 
system, and each image is identified with a time stamp. Thus, the position of the patient‟s chest 
wall as a function of time is saved as a RPM system file. 
 
Figure 3.2: Varian RPM system 4DCT infrared camera mounted at base of CT 
couch (left) and the Quasar respiratory phantom affixed with the RPM marker box 
(blue circle) as seen from the camera‟s point of view (right) 
In 4DCT acquisition, a cine CT is acquired, where the couch remains stationary during 
data acquisition, then indexes to the next couch position until desired field-of-view is imaged. 
Once the scan is completed, the cine CT scan data and the RPM chest wall motion data are sent 
to the GE Advantage computer for sorting. The sorting program takes the cine scan data, and 
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correlates the timestamp on each projection image to the RPM file to determine the relative chest 
wall amplitude level for each projection. Then the projection data images are sorted by the 
computer into 10 distinct phases ranging from full inhale (0% phase) to full exhale (50% phase) 
and back to inhale using the relative chest wall amplitude. The technical aspects of the 
acquisition and reconstruction of the 4DCT images are discussed elsewhere in literature (3.8, 3.9, 
3.10). The phase-sorted projection images are recombined to create a unique CT data set for each 
phase. Additionally, the computer uses the entire cine scan to produce a maximum-intensity 
projection (MIP), minimum-intensity (Min-IP) dataset, and an average intensity (Avg-IP) data 
set.  The sorting computer creates the MIP by examining each pixel and assigning each pixel the 
highest value observed at that location over all ten phase-sorted images. Similarly, the Avg-IP 
and Min-IP data sets show the average and minimum pixel value, respectively, observed over all 
ten phases. The MIP is particularly important since as a solid tumor moves, the MIP shows the 
extent of tumor motion over all phases of respiration. Currently, the MIP is used to establish the 
extent of tumor respiratory motion to design the radiation beams that fully encompass the tumor 
motion.   
3.1.4 ExacTrac System 
The ExacTrac (ET) Gating system was developed by BrainLab (Munich, Germany) to 
allow image guidance and respiratory gating on the Novalis linear accelerator. This system 
combines two kilo-voltage (kV) x-ray tubes, two amorphous silicon image detector panels, an 
infrared optical camera system, and an interface to the linear accelerator. Figure 3.3 shows a 
conceptual picture of how the kV x-ray tubes project through the patient onto the detector panels. 
Figure 3.4 shows the flat panel detectors and Figure 3.5 is a picture of the floor mounted x-ray 
tube with and without covers.  
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Figure 3.3: Conceptual picture of the ExacTrac kV orthogonal x-rays (courtesy of 
BrainLab). 
 
 
 
 
Figure 3.4: Picture of the ExacTrac amorphous silicon image detector mounted to 
the ceiling.  
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Figure 3.5: Picture of covered kV x-ray housing panel in floor (left) and with 
cover removed (right) 
 This system is installed on a Novalis (BrainLab, Munich, Germany) therapy machine, 
which is a 6 MV linear accelerator with a BrainLab M3 micro-multileaf collimator. The ET 
gating software monitors external bodymarkers (seen in Figure 3.1) and only allows radiation 
delivery when the markers are within a predetermined window of respiratory amplitude. 
Radiation output constancy has been reported to be better than 0.5% when the radiation beam 
was gated in situations with many beam interruptions, as compared to a non-gated delivery (3.5). 
 The ET gating system uses a combination of infrared/optical and x-ray tracking to setup 
and monitor the patient and, ultimately, to deliver the gated treatment. The breathing signal 
tracked by the ExacTrac system is based on the vertical movement of infrared reflecting 
bodymarkers attached to the patient/phantom as seen by the infrared camera. The camera system 
consists of two independently mounted infrared cameras along with a video camera for visual 
monitoring on a rail above the foot of the treatment couch, as seen in Figure 3.6. To eliminate the 
influence of any couch movement on the observed breathing trace, a stationary reference object 
is also monitored by the cameras. As a stable reference object, BrainLab has developed the 
“Reference Star” which consists of 4 infrared reflecting pads held in a known trapezoidal 
configuration supported by an arm mounted to the side of the treatment couch. The Reference 
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Star is shown in Figure 3.7 mounted over a phantom on the Novalis treatment couch. The ET 
system illuminates and observes the moving patient-mounted bodymarkers as well as the 4 
reflecting pads of the Reference Star. The breathing motion is calculated from the relative 
positions of the external patient bodymarkers as compared to the stationary markers on the 
Reference Star. Yan et al. provides a description of how the ExacTrac system resolves the three 
dimensional position of the markers from the two dimensional camera information (3.6) 
First, the user selects the reference gating level in the ExacTrac system. At this point in 
the respiratory cycle, the target isocenter will be placed at the machine isocenter. When the 
patient‟s chest wall amplitude, as monitored by the ET Bodymarkers, matches the reference 
gating level (near full-exhale for our studies), ExacTrac acquires an image from an x-ray 
imaging panel. A subsequent image is taken on another respiration but at the same point of the 
respiratory trace with the other x-ray tube after the user has confirmed the first image is 
acceptable. Once both images are accepted, digitally reconstructed radiographs (DRR) 
corresponding to the x-ray tube/flat panel imager orientations are calculated from the planning 
CT dataset by ExacTrac and compared to the ExacTrac x-ray images. Figure 3.8 shows an 
example of a DRR created from the 4DCT dataset compared to a corresponding image from the 
ExacTrac x-ray imaging system. ExacTrac calculates a position shift corresponding to the 
difference of the current ExacTrac setup and planned target location by correlating the DRR 
from the CT and daily setup x-rays (using anatomy, implanted fiducials, etc.). 
The patient/phantom is repositioned so that the target is at the isocenter of the beam when 
the breathing trace intersects the gating reference level. The shift to reposition the patient is 
calculated by the ExacTrac software. When using implanted fiducial alignment, the user-defined 
position of the coil in planning CT dataset is used to align the position of the coil as calculated 
from the imaged coil position from the kV x-ray panels. 
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Figure 3.6: The infrared camera system mounted in the Novalis room. The red 
circles indicate the infrared cameras used for monitoring the external BrainLab 
bodymarkers. The blue circle identifies as an optical-light camera for visual 
monitoring. 
 
 
Figure 3.7: The ET Reference Star (circled in red) is shown mounted over a 
phantom on the Novalis treatment couch. 
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Figure 3.8: Comparison of the DRR from the 4DCT (left) and a corresponding kV 
x-ray image from ExacTrac. The orange cross in the left image represents the 
planning isocenter. When the user identifies the location of the coil in the DRR 
and ExacTrac images, the system calculates the location of the planning isocenter 
to the machine isocenter 
The right panel of Figure 3.8 shows the coil is displaced from the DRR constructed from 
the planning CT dataset (left). The ExacTrac will calculate a 3-dimensional shift to place the coil 
at the same position as seen the planning CT dataset.  
Images at respiration levels other than the gating reference level can be taken as well, 
allowing the user the ability to determine coil/tumor motion/position at other amplitude levels. 
Once the imaging is complete and the patient is aligned, treatment is enabled. The treatment 
beam is then gated on for a percentage of the relative respiratory trace centered about the gating 
reference level.  
To image at a pre-selected respiratory amplitude level, the ExacTrac software takes 
several factors into account. The ET software extrapolates the breathing motion from the external 
markers and estimates when the measured breathing amplitude will match the desired imaging 
amplitude. The imaging panels must be continuously read out to remove charge that may have 
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built-up on the pixel electrode due to dark current. The software must manage the readout to 
ensure a “clean” detector panel is ready to acquire an x-ray exposure, and to time the mid-point 
of the acquisition to be at the anticipated moment the breathing amplitude matches the imaging 
amplitude. The software must time the start of the exposure to occur at half of the exposure time 
before the desired time of exposure. When imaging a moving target such as the coil inside the 
ET phantom, we are actually measuring the accuracy of the predictive algorithm to acquire the x-
ray image when it anticipates the target to be in the requested imaging amplitude.  
The ExacTrac predictive breathing algorithm for x-ray acquisition only cues off the 
patient‟s respiratory motion from full inhale (0% Phase, 100% Amplitude) to full exhale (50% 
Phase, 0% Amplitude). Thus, ExacTrac can only produce images which would correspond to 
4DCT phase images from 0% to 50%. 
 The size of the gating window should be determined based on the desired additional 
margins used for treatment planning, or vice versa. By restricting the gating window to a very 
narrow range of chest wall amplitudes during respiration, the target movement during the beam-
on time will be reduced. However, the overall treatment time will be expanded due to the limited 
beam-on time. Once the patient is correctly positioned and target position is verified at the gating 
reference level, ExacTrac gates the treatment delivery from the linear accelerator when the 
respiratory markers are observed to be within the gating window. At any time during the 
treatment, the user can acquire additional x-ray images to ensure that proper patient positioning 
is maintained, even if changes in the patient‟s respiratory characteristics are suspected.  
3.2 Methods and Materials 
To determine the coil localization accuracy of the ET Gating system in comparison to the 
4DCT, this aim acquired 4DCT scans using the Quasar respiratory phantom with a preselected 
assortment of respiratory amplitudes (5-25 mm) utilizing sinusoidal one-dimensional motion. 
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The 4DCT data was sorted by the GE 4DAdvantage software and files were prepared for import 
into Pinnacle
3
 (Philips Medical Systems, Bothell, WA) treatment planning system (TPS) version 
8.0, hereafter referred to as the Pinnacle TPS. In Pinnacle, the user identified the endpoints of the 
implanted coil in each respiratory phase. The identified coil endpoint data from each phase was 
extracted to determine the overall coil motion from phase to phase for the 4DCT data. 
With identical phantom motion parameters, ExacTrac images were acquired at each 
phase investigated on the 4DCT dataset. The software reported the locations of the coil 
midpoints in the ExacTrac coordinate system. The measured coil motions in the ExacTrac and 
4DCT systems were compared to the expected coil displacements over the tracked phases of 
respiration. Because the Quasar phantom motion moves with sinusoidal motion with specified 
amplitude and period, the overall motion of the coil is known for all phases of respiration.  
3.2.1 The Quasar Motion Phantom 
The Quasar phantom was shown in Figure 3.1 with a wooden canister insert designed to 
simulate a patient‟s lung. The canister was modified to accept a Visicoil by scoring the anterior 
outer surface of the cylinder. The coil was secured in the wooden insert so that it would not 
move during phantom motion. 
For our studies, the solid blue piece of foam affixed to the platform represents the patient 
chest wall, which moves in the anterior-posterior (AP) direction. The blue foam board was added 
to provide a wider chest platform that could be removed from the phantom if needed. This setup 
gives the external chest markers uniform motion amplitude in the AP direction. The ExacTrac 
Gating system triggers the radiation delivery based on the marker motion detected by the 
cameras. The bodymarkers shown in Figure 3.1 reflect the infrared (IR) light back to the camera 
system mounted above the foot of the couch, previously seen in Figure 3.6.   
 51 
The Quasar phantom was tracked by the ExacTrac infrared camera system, observing the 
motion of the reflecting bodymarkers for an extended period of time (~10 minutes). The relative 
position of the markers was recorded by the ExacTrac system. The Quasar phantom‟s marker 
motion matched a sinusoidal curve. The Quasar phantom was observed to be sinusoidal, stable, 
and repetitive.  
3.2.2 Implanted Markers 
An internal marker (Visicoil; RadioMed Corporation, Tyngsboro, MA) was used as a 
surrogate for internal tumor motion. Figure 3.9 shows a sample Visicoil imbedded in plastic. The 
Visicoil markers used for this project measured 30.8 mm in length, and 0.8 mm in diameter.
 
Figure 3.9: An example of the Visicoil inserted into the Quasar moving canister 
for imaging purposes. 
3.2.3 Phantom Motion Criteria 
In order to evaluate the 4DCT and ExacTrac systems independently, it was necessary to 
standardize the phantom characteristics that will be measured in each system. First, it was 
determined what overall tumor motion to replicate with our phantom. AAPM Report 91 (3.11) 
recommends that respiratory gating should be considered only when tumor respiratory motion 
exceeds 5 mm. Ionascu et al. reports that, for most patients, a superior-inferior tumor movement 
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over 20 mm is relatively uncommon (3.3). Thus, this work restricted the phantom respiratory 
motions to amplitudes of 5, 10, 15, 20 and 25 mm motion in the SI direction.  
 
Figure 3.10: MBPCC Respiratory period histogram from 34 patients scanned with 
clinical 4DCT protocol recorded by the Varian RPM system. 
The patient chest wall motion is mimicked by the marker platform of the Quasar 
phantom. This project looked at patient data from the Varian RPM system to determine a value 
for the phantom respiratory period settings. 4DCT patient data were analyzed to obtain an 
average respiratory period. Of 50 patients with RPM files, only 34 had reproducible and 
sustained breathing traces recorded. Most of the 34 patients had respiratory periods of 3-5 
seconds (Figure 3.10). The average for all 34 patients was 3.7 ± 0.8 seconds. This correlates well 
with findings by Seppenwoolde that report an average respiratory period of 3.6 ± 0.8 seconds 
(3.12). 
 Also of interest is that the RPM system records the length of time the patient spent in 
exhale phases and inhale phases. For the 34 patients studied, an average exhalation length of 2.1 
seconds was observed compared to an average inhalation length of 1.5 seconds. This agrees with 
the observations reported in literature (3.12). Thus, a treatment that places a gating window 
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about the exhalation phases of respiration would have a larger percentage of time with the beam 
enabled, resulting in a relative decrease in the treatment time.  
3.2.4  4DCT Methods 
All 4DCT scans taken during this project utilized the current clinical protocols. A slice 
thickness of 2.5 mm for four slices per cine was used so that at each couch position, the coverage 
is 10 mm in the cranial-caudal direction.  X-ray tube settings of 120 kV and 440 mA were used. 
The phantom was scanned at 1.0 second per revolution gantry speed rotation. The current clinical 
protocols recommend a cine duration time equal to the breathing period of the patient plus 2.0 
seconds, so cine duration was set to 6.0 seconds. 
The phase-sorted datasets were reconstructed and sent to the Pinnacle TPS. Due to 
current limitations in the Pinnacle planning software, the description field containing the phase 
information cannot be viewed when importing the datasets into a plan. Thus, the user cannot 
identify the phase-sorted datasets. Connel Chu, M.S. at MBPCC has developed a program which 
pulls the phase-sorted datasets from the Pinnacle import directory, appends the image dataset 
name with the description field, and replaces the old files with the new renamed files. Then, the 
user can identify the phase value for each image set when importing the data into Pinnacle. Once 
all 10 phase-sorted datasets were imported, along with the 3 intensity projection images, and 
possibly a helical scan, up to 14 datasets were associated with each plan.  
3.2.5 4DCT Coil Motion Study 
In order to evaluate the effects of respiratory motion on the 4DCT images of the 
implanted coil, the 4DCT process was repeated five times on the Quasar phantom for amplitudes 
of 5, 10, 15, 20 and 25 mm. Separate phantom-based patients were created where all phase-
sorted datasets were imported for each of the scanned amplitudes. Utilizing a bone-optimized 
viewing window in the Pinnacle TPS, both the superior and inferior ends of the implanted coil 
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were identified on each phase. Each point was assigned as a point-of-interest (POI) in Pinnacle. 
This information was exported to Excel to calculate the overall detected coil length. This was 
compared to the known physical coil length to determine error in imaging the coil length in each 
phase.  
The actual distance the coil endpoints moved between phases was also determined from 
the programmed sinusoidal motion of the phantom. The measured motion of the coil endpoints 
was then compared to the actual motion of the coil to determine the accuracy of the 4DCT in 
localizing a coil over all respiratory phases. 
3.2.6 ExacTrac Coil Motion Study 
 Three tests were conducted for this study. First, since the user must select the coil 
endpoints on each x-ray image from the ExacTrac system, the reproducibility of the user‟s coil 
selection was investigated on a non-moving phantom. Next, with a moving phantom/coil, the 
repeatability of the ExacTrac in imaging the coil at the same location was tested. In the final test, 
the moving phantom was imaged over a subset of amplitude levels. The measured coil 
displacements were compared to the expected coil displacements for a coil moving with 
sinusoidal motion.  
In the first test, the stationary phantom was repeatedly imaged by the ExacTrac system, 
and the coil endpoints were identified on each image. Since the coil was stationary, the only 
variation in the system was the user identifying the coil endpoints. Figure 3.11 shows a sample 
pair of x-rays taken from the Quasar phantom showing the implanted coil. The ExacTrac system 
calculated the three-dimensional position of the coil from each set of images. 
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Figure 3.11: A pair of x-ray images obtained from the ExacTrac system used to 
identify the location of the implanted Visicoil. Coil is circled in red at the top left 
(left image) and top right (right image) 
The second test involved moving the phantom at the maximum target motion amplitude 
used during this study (25 mm). This is a test to measure the maximum error in target 
localization. At the 50% amplitude of the sinusoidal motion, the coil is moving at the fastest 
velocity. At 50% amplitude of a 25 mm target motion, the phantom was imaged repeatedly to 
determine the variation in coil localization.  
 The third test measured the overall accuracy in the ExacTrac system to identify the 
position of the moving coil. To test the coil localization accuracy, the phantom‟s amplitude was 
set at 5, 10, 15, 20 or 25 mm target motion and imaged at amplitude levels that correspond to 
phases (0, 10, 20, 30, 40 and 50%) imaged in the 4DCT study. The relative motion of the coil in 
each phase was compared to the actual motion of the sinusoidal phantom for each respiratory 
amplitude/phase combination over all five motion amplitudes. Once images at all selected levels 
were obtained, the positions of the implanted coil endpoints were identified. Then, the ExacTrac 
system calculated the locations of the coil endpoints. For each imaging panel, x-ray settings of 
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100 kV and 200 mA were used, as this gave a clear image of the implanted coil. For every 
image, the ExacTrac gating system requires the x-ray duration equal 100 milliseconds.  
Because the Quasar phantom moved in a consistent sinusoidal motion, the ET software 
should be able to extrapolate the breathing signal with minimal error. Relative amplitude levels 
of 0, 9.5, 34.5, 65.5, 90.5 and 100 percent correspond to respiratory phases of 50, 40, 30, 20, 10, 
and 0 percent, respectively, for a sinusoidal curve. These amplitude levels were the same, no 
matter what coil motion amplitude was selected. The imaging amplitude levels were set as 
defined above, and an image was acquired from each x-ray panel. 
3.3 Results  
3.3.1 4DCT Coil Endpoint Selection Accuracy 
 The user errors in identifying coil ends in 4DCT images are shown in Table 3.1 
for 50% (full-exhale) phase and in Table 3.2 for mid-exhale phase (20%). The variation of in 
user identification has a maximum standard deviation of 0.5 mm. The results demonstrate that 
the user‟s ability to repeatedly select the coil endpoints is not affected by the phase dataset 
observed.  We can assume a user can localize the same coil endpoints on any phase-sorted CT 
dataset to within half a millimeter for the purposes of this project. In the Pinnacle coordinate 
system, the z-axis is the direction of coil motion, therefore we would expect the error in that 
direction to be slightly larger since the coil distortion and blurring would be in the z-direction.  
The z-direction is also in the direction of slice thickness, which has a lower spatial resolution 
than the other two axes. 
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Table 3.1: Reproducibility of 4DCT coil endpoint selection by user for full-exhale 
phase (all values in cm) 
 50% Phase (full exhale) 
 Superior Endpoint Coordinates  Inferior  Endpoint Coordinates 
 X (cm) Y (cm) Z (cm)  X (cm) Y (cm) Z (cm) 
attempt 1 10.03 -46.33 0.64  10.11 -46.31 3.83 
attempt 2 10.04 -46.33 0.68  10.13 -46.31 3.85 
attempt 3 10.03 -46.33 0.66  10.13 -46.32 3.82 
attempt 4 10.05 -46.33 0.76  10.11 -46.31 3.81 
attempt 5 10.08 -46.33 0.70  10.09 -46.30 3.85 
        
1 σ 0.02 0.00 0.05  0.02 0.01 0.02 
 
 
 
Table 3.2: Reproducibility of 4DCT coil endpoint selection by user for mid-
exhale phase (all values are in cm) 
 20% Phase (mid-exhale) 
 Superior Endpoint Coordinates  Inferior Endpoint Coordinates 
 X (cm) Y (cm) Z (cm)  X (cm) Y (cm) Z (cm) 
attempt 1 10.02 -46.33 -1.29  10.11 -46.33 2.83 
attempt 2 10.02 -46.31 -1.28  10.11 -46.36 2.90 
attempt 3 10.02 -46.34 -1.34  10.12 -46.36 2.86 
attempt 4 10.03 -46.31 -1.34  10.11 -46.33 2.81 
attempt 5 10.01 -46.33 -1.33  10.11 -46.31 2.94 
        
1 σ 0.01 0.01 0.03  0.00 0.02 0.05 
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3.3.2 ET Coil Endpoint Selection Accuracy 
 Table 3.3 shows, for 11 repeat acquisitions in the ET Gating system, the coordinate 
locations of the coil with respect to machine isocenter as determined by the kV x-ray imaging 
system. The first entry is at the origin of the coordinate system because the ExacTrac x-ray setup 
was used to position the stationary phantom such that the coil was at machine isocenter. On 
subsequent imaging sessions, the system should register no correction shift. For each following 
test in Table 3.3, the correction shift in all three axes was recorded. The results in Table 3.3 show 
that the user can select a non-moving coil‟s endpoints with an accuracy of less than a tenth of a 
millimeter (<0.06 mm). 
 To quantify the overall reproducibility of the ET Gating system, the Quasar 
phantom was set to 25 mm respiratory motion, to simulate the largest amplitude we would expect 
to see clinically. The ET Gating system was used to image the 50% relative amplitude level of 
the moving coil. The results are shown in Table 3.4. The coordinate set is the coil location with 
respect to machine isocenter established during attempt #1. The variation of the ExacTrac system 
in repeatedly imaging the fast moving coil is less than 0.2 mm at one standard deviation in the 
direction of motion.  
 In summary, the position of a stationary coil can be identified to within 0.5 mm in 4DCT 
images and to within 0.1mm in ExacTrac images. A moving coil could be located to within 0.2 
mm in the direction of motion in the ET system. 
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Table 3.3: Repeat ET Gating imaging of the positions of a stationary coil 
midpoint to test a user‟s ability to repeatedly identify the coil endpoints.  Listed 
are the ExacTrac coordinates of the coil midpoint as calculated from the user-
selected coil endpoints.  
  X (mm) Y (mm) Z (mm) 
Attempt 1 0.00 0.00 0.00 
Attempt 2 -0.01 -0.13 -0.06 
Attempt 3 -0.02 0.00 -0.05 
Attempt 4 -0.05 -0.07 -0.08 
Attempt 5 0.03 -0.09 -0.03 
Attempt 6 -0.13 0.06 -0.07 
Attempt 7 0.09 -0.05 -0.06 
Attempt 8 0.07 0.00 -0.09 
Attempt 9 0.00 -0.03 -0.04 
Attempt 10 0.01 -0.06 -0.09 
Attempt 11 0.04 -0.09 -0.07 
        
Average 0.00 -0.04 -0.06 
1 σ 0.06 0.05 0.03 
 
 
Table 3.4: Repeat ET imaging of a coil undergoing 25mm sinusoidal motion at 
50% amplitude. All values in mm.  
  X (mm) Y (mm) Z (mm) 
Attempt 1 0.00 0.00 0.00 
Attempt 2 0.04 -0.22 0.16 
Attempt 3 0.06 -0.13 0.15 
Attempt 4 0.08 -0.20 0.13 
Attempt 5 0.08 0.06 0.09 
Attempt 6 0.08 0.13 0.19 
Attempt 7 0.02 0.25 0.01 
Attempt 8 0.08 -0.07 0.32 
Attempt 9 -0.04 -0.23 0.09 
Attempt 10 0.01 -0.11 0.00 
Attempt 11 0.01 -0.22 0.13 
        
Average 0.04 -0.07 0.12 
1σ 0.04 0.16 0.09 
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3.3.3 4DCT Coil Motion Distortion Results 
Initial results from the 4DCT showed that motion artifacts are minimal at end-inhalation 
and exhalation respiratory phases (0 and 50% phase respectively). At intermediate phases, the 
coil is moving with velocity dependant on the phase of the sinusoidal motion observed. Table 3.5 
shows the error (in millimeters) of the measured coil length for all 10 phases of respiration for all 
five amplitudes observed. Measured coil length was determined by calculating the distance in 
space between the two coil endpoints as identified by the user in the Pinnacle coordinate system. 
The actual physical length of the coil was 30.8 mm. 
Table 3.5: Errors in 4DCT detected coil length over all phases for selected motion 
amplitudes. All values in mm. 
Phase  5 mm 10 mm 15 mm 20 mm 25 mm 
0%  0.0 0.5 0.7 0.7 0.4 
10%  0.7 0.1 1.1 1.1 0.6 
20%  0.6 1.1 1.6 1.2 8.1 
30%  0.6 1.0 0.5 1.2 8.3 
40%  0.4 1.0 1.4 0.9 1.5 
50%  0.2 0.3 0.8 0.1 0.7 
60%  0.0 0.1 1.4 0.8 0.6 
70%  0.3 1.1 1.9 3.4 2.9 
80%  0.3 1.6 1.3 1.5 3.4 
90%  0.5 0.8 0.0 2.2 1.3 
 
For the 0 and 50 percent phases (full-inhale and full-exhale, respectively) in which the 
coil was moving the least, the error in the measured coil length was the least. At these phases, the 
maximum measured distortion in the coil length was 0.8 mm at the 50% phase of the 15 mm 
motion profile. When the coil was moving the fastest, at mid-inhale for example, the errors in the 
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coil length grew larger as the overall coil displacement grew, as was expected.  At 25% and 75% 
phases (corresponding to 50% amplitude of the sine curve), the coil had the highest velocity, thus 
the 20, 30, 70, 80% phases should show the most coil distortion. At 25 mm respiratory 
amplitude, 8.1 and 8.3 mm errors in the coil length were observed at 20 and 30% phase, while at 
end respiration phases, the coil length distortions were minimal (0.7 and 0.4 mm). Thus, coil 
distortion was minimized on full-exhale and full-inhale phase datasets. If one assumes the 
detected coil distortion to reproduce the distortion of any moving tumor volume, then the errors 
in detecting both the coil and target tumor volume would be minimized by selecting the end-
exhalation or inspiration datasets. In general motion artifacts in the 4DCT datasets are minimized 
at phases where the coil motion is minimized, corresponding to full-exhale and full-inhale of the 
respiratory cycle. For treatment planning purposes, this study suggests using the full-exhale 
(50%) phase for all patients to minimize motion-induced distortion on the planning dataset.  
3.3.4 Coil Localization Results 
 For each phase of the sinusoidal respiratory motion of the Quasar phantom, the 
displacement of the coil in each phase was calculated. This calculated shift was compared to the 
shifts observed in the 4DCT datasets and with the ET Gating system. The data for both the 
superior and inferior points of the coil can be compared to the expected displacement from the 
previous phase.  
 In Table 3.6 the results of the coil localization comparison of the ET gating system to the 
4DCT are given in millimeters. For reference, the 4DCT phase is correlated to the matching 
ExacTrac amplitude of the sinusoidal motion of the phantom in the first two columns. The CT 
Sup and CT Inf columns refer to the superior and inferior coil endpoints in the 4DCT data, 
respectively. To compare these two different systems with different coordinate system origins, 
the 50% phase data set was taken to be the origin of the coordinate system used to display the 
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data. From this origin, the relative displacement of the 4DCT derived coil endpoints are given in 
CT Sup and CT Inf. In the next two columns, ET 1 and ET 2 refer to two separate measurements 
of the ET Gating software where the coil was imaged at the ET amplitude given in the first 
column. The ET system does not give the user the location of the coil endpoints, but a “center of 
mass” of the coil points. This coil center displacement can be tracked throughout all of the 
amplitudes which correspond to the 4DCT phases measured in third and fourth columns. Two 
ExacTrac measurements were performed to provide additional displacement data to contrast with 
the two endpoint displacement studies from the 4DCT.  
Finally, the “Calc Dist” column of Table 3.6a-e uses the overall measured phantom 
motion to mathematically calculate the displacement of a point moving with the measured 
sinusoidal motion. This column is a mathematical calculation from of the displacement of a sine 
curve at the phases observed (0-50%). The measured displacement of the coil as measured by the 
ExacTrac and 4DCT systems should match that of the calculated distance.  
For a better illustration of the errors encountered in either system, Table 3.7 expresses the 
data above in terms of error from the Calc Dist column. As seen in the table, the maximum errors 
in the ET Gating systems are 0.7 and 0.8 mm, respectively, for the two ExacTrac trials. The 
maximum error in the 4DCT displacement was 5.5 mm. As the amplitude decreases, the 4DCT 
shows better accuracy in localizing the coil. In the ET Gating system, a similar increase in 
accuracy is noted when the coil motion amplitude is decreased. However, at larger amplitudes, 
the ET Gating system can still localize the coil to sub-millimeter accuracy.  
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Table 3.6 a-e: Comparison of 4DCT vs. ET Gating coil localization 
a. Quasar 5 mm Motion Results (mm) 
ExacTrac CT Phase CT Sup CT Inf ET 1 ET 2 Calc Dist 
0.0% 50% - - - - 0.0 
9.5% 40% 0.7 0.9 0.5 0.4 0.5 
34.5% 30% 1.3 1.7 2.1 2.0 1.9 
65.5% 20% 4.1 4.5 3.7 3.8 3.6 
90.5% 10% 4.8 5.3 5.1 5.2 5.0 
100.0% 0% 6.1 5.9 5.5 5.6 5.5 
              
b. Quasar 10 mm Motion Results (mm) 
ExacTrac CT Phase CT Sup CT Inf ET 1 ET 2 Calc Dist 
0.0% 50% - - - - 0.0 
9.5% 40% 1.1 0.4 1.0 0.7 1.0 
34.5% 30% 2.7 2.0 3.7 3.7 3.5 
65.5% 20% 6.8 6.0 6.9 6.9 6.6 
90.5% 10% 8.9 9.1 9.2 9.3 9.1 
100.0% 0% 10.0 9.8 10.3 10.1 10.0 
       
c. Quasar 15 mm Motion Results (mm) 
ExacTrac CT Phase CT Sup CT Inf ET 1 ET 2 Calc Dist 
0.0% 50% - - - - 0.0 
9.5% 40% 1.0 0.4 1.8 1.6 1.4 
34.5% 30% 1.7 3.0 5.8 5.9 5.2 
65.5% 20% 6.7 5.9 10.5 10.6 9.8 
90.5% 10% 11.5 13.4 13.8 14.1 13.6 
100.0% 0% 13.8 13.9 15.4 15.5 15.0 
       
d. Quasar 20 mm Motion Results (mm) 
ExacTrac CT Phase CT Sup CT Inf ET 1 ET 2 Calc Dist 
0.0% 50% - - - - 0.0 
9.5% 40% 1.0 0.2 1.6 1.8 1.9 
34.5% 30% 7.5 6.4 7.6 7.2 6.9 
65.5% 20% 11.9 10.8 13.4 13.5 13.1 
90.5% 10% 16.6 17.8 18.1 17.9 18.1 
100.0% 0% 18.9 18.3 20.2 19.9 20.0 
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(Table 3.6 cont.) 
e. Quasar 25 mm Motion Results (mm) 
ExacTrac CT Phase CT Sup CT Inf ET 1 ET 2 Calc Dist 
0.0% 50% - - - - 0.0 
9.5% 40% 2.8 2.0 2.3 2.7 2.4 
34.5% 30% 12.1 4.5 9.2 9.4 8.8 
65.5% 20% 18.6 11.2 17.3 17.4 16.7 
90.5% 10% 22.3 23.6 23.1 23.3 23.1 
100.0% 0% 24.4 24.7 25.4 25.2 25.5 
 
Table 3.7a-e: Comparison of errors of the 4DCT vs. ET Gating system. The 
largest observed errors are highlighted for each data set. 
a. Quasar 5 mm Motion Results (mm) 
ExacTrac CT Phase CT Sup CT Inf ET 1 ET 2 
0.0% 50% - - - - 
9.5% 40% 0.2 0.4 0.0 -0.1 
34.5% 30% -0.6 -0.2 0.2 0.1 
65.5% 20% 0.5 0.9 0.1 0.2 
90.5% 10% -0.2 0.3 0.1 0.2 
100.0% 0% 0.6 0.4 0.0 0.1 
      
b. Quasar 10 mm Coil Localization Errors (mm) 
ExacTrac CT Phase CT Sup CT Inf ET 1 ET 2 
0.0% 50% - - - - 
9.5% 40% 0.1 -0.6 0.0 -0.3 
34.5% 30% -0.8 -1.5 0.2 0.2 
65.5% 20% 0.2 -0.6 0.3 0.3 
90.5% 10% -0.2 0.0 0.1 0.2 
100.0% 0% 0.0 -0.2 0.3 0.1 
      
c. Quasar 15 mm Localization Errors (mm) 
ExacTrac CT Phase CT Sup CT Inf ET 1 ET 2 
0.0% 50% - - - - 
9.5% 40% -0.4 -1.0 0.4 0.2 
34.5% 30% -3.5 -2.2 0.6 0.7 
65.5% 20% -3.1 -3.9 0.7 0.8 
90.5% 10% -2.1 -0.2 0.2 0.5 
100.0% 0% -1.2 -1.1 0.4 0.5 
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(Table 3.7 cont.) 
d. Quasar 20 mm Localization Errors (mm) 
ExacTrac CT Phase CT Sup CT Inf ET 1 ET 2 
0.0% 50% - - - - 
9.5% 40% -0.9 -1.7 -0.3 -0.1 
34.5% 30% 0.6 -0.5 0.7 0.3 
65.5% 20% -1.2 -2.3 0.3 0.4 
90.5% 10% -1.5 -0.3 0.0 -0.2 
100.0% 0% -1.1 -1.7 0.2 -0.1 
      
e. Quasar 25 mm Localization Errors (mm) 
ExacTrac CT Phase CT Sup CT Inf ET 1 ET 2 
0.0% 50% - - - - 
9.5% 40% 0.4 -0.4 -0.1 0.3 
34.5% 30% 3.3 -4.3 0.4 0.6 
65.5% 20% 1.9 -5.5 0.6 0.7 
90.5% 10% -0.8 0.5 0.0 0.2 
100.0% 0% -1.1 -0.8 -0.1 -0.3 
 
 
3.4 Conclusions 
This works concludes that when identifying a coil on phase-sorted 4DCT datasets taken 
with our clinical protocols, a user can locate the coil endpoints with a variation less than 0.5 mm. 
From 4DCT studies of the measured coil length, it was determined that at full-exhale and full-
inhale phases of respiration, motion-induced artifacts of a coil are less than a millimeter. The 
4DCT phase-sorted datasets corresponding to full-exhale and full-inhale provide the most 
accurate image of the moving phantom or patient. Due to the mechanics of breathing, exhalation 
phases in patients are more stable and reproducible than inhalation phases. This project 
recommends using a full-exhale dataset for treatment planning system calculations and gating the 
radiation treatment about the full-exhale (50%) phase of respiration.  
When determining the extent of a patient‟s respiratory motion with an implanted 
surrogate such as a coil, the ExacTrac system performs better than 4DCT at coil localization. 
 66 
With the ExacTrac system‟s ability to localize a coil to sub-millimeter accuracy, it is reasonable 
to expect ExacTrac to be able to localize a moving coil in a patient with well-behaved (no 
coughing or gasping) chest wall motion. To accurately determine the direction and extent of 
patient‟s internal respiratory motion after coil implantation, this aim recommends using the 
ExacTrac system.  
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4 Aim 3: Measure the Spatial Distribution of Dose to a Moving 
Phantom Using a Variety of Gating Window Levels and 
Amplitudes for Sinusoidal Motion. 
4.1 Introduction 
This aim studied ITV margins for various target motions and gating window levels such 
that gated delivery produced the same 95% therapeutic dose coverage as delivery to a stationary 
phantom. With any target motion and gating window level used, it may be expected that 
expanding the field size in the direction of motion by the total amplitude of the motion during the 
gating window (residual motion) would fully re-achieve the target coverage as observed in the 
static phantom delivery. The residual motion is dependent on the direction of motion, the 
magnitude of motion, and the percent amplitude of the respiratory cycle gating window level 
covers. This aim will investigate if expansion by the residual motion is adequate to maintain 
target coverage in the respiratory phantom.  
This aim also determined which gating window levels limited ITV expansions to less 
than 3mm for target motions less than 25 mm. Recommendation for ITV expansions were 
developed for delivery to the Quasar respiratory phantom. Finally, dose-volume differences 
between gated and a non-gated delivery were estimated. 
4.2 Methods and Materials 
A standardized treatment plan was created and delivered to the Quasar phantom. Gated 
delivery to the Quasar phantom in motion was compared to non-gated treatment delivery to the 
stationary phantom using radiochromic film measurements.  
4.2.1 Pinnacle Treatment Planning 
 A 4DCT scan of the Quasar phantom with the film canister in place and moving with 20 
mm amplitude was taken using the same cine CT scan conditions as outlined in Aim 2 (2.5 mm 
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slice thickness, 120 kV, 440 mA, 6 second cine duration.) The CT dataset at 50% phase (full 
exhale) was extracted. This phase shows the implanted coil with the least distortion over all 
phases, as measured in Aim #2. Full exhale was used as the reference gating level for all 
treatments in this study.  
 A 3-cm long by 3-cm diameter cylindrical region of interest (ROI) was created in the 
center of the film canister with the long axis of the ROI cylinder coinciding with the long axis of 
the canister. This region of interest was considered to be the planning CTV (CTVPlan) solely for 
placing the treatment beams and optimizing the beam weights. The plane containing the 
radiochromic film corresponded to a coronal slice through the phantom and passed through the 
center of the cylindrical CTVPlan.  
 Nine co-planar beams were placed at 40 degree intervals around an isocenter located in 
the center of the CTVPlan. This selection of a cylindrical CTVPlan and a coplanar beam 
arrangement simplified the shape of the treatment beams because from all nine beam‟s eye views 
the CTVPlan appeared as a 3x3 cm
2
 square. The collimator of the linear accelerator was rotated 
such that the multi-leaf collimator leaves moved in the direction of target motion, allowing for 
continuous margin expansions in the direction of motion. This orientation was chosen because 
expansions perpendicular to leaf motion would have to be discrete steps of distance equal to the 
leaf widths. All beams were opened to a 3.6x3.6 cm
2
 leaf-defined field size in order to cover the 
CTVPlan with the prescription dose. The Novalis linac is capable of 6 MV photon beam output 
only, and the plan was designed accordingly.  
The prescription dose was set at 400 cGy in order to reach the middle of the dynamic 
range of radiochromic EBT film. The Pinnacle system optimized the monitor units (MU) for 
each beam to attempt to provide a uniform dose of 400 cGy to the CTVPlan. 
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Figure 4.1: Pinnacle TPS orthogonal views of the conformal radiotherapy plan 
delivered to Quasar phantom. The planning data set is the 50% phase (full-
exhale). The top left view is an axial view, top right is sagittal, and the bottom left 
view is a coronal slice. All three views were through the CTVPlan isocenter. The 
bottom right view the nine beam arrangement placed around the CTVPlan 
isocenter. The canister/target motion is in the superior-inferior direction.  
Figure 4.1 shows a screenshot from the Pinnacle TPS containing three orthogonal views 
of the treatment plan on the 50% phase dataset and a 3D rendering of the phantom and beam 
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arrangements.  The light blue region in Figure 4.1 is the CTVPlan, and the dark red line signifies 
the 95% isodose line. The goal of the TPS beam weighting optimization was to uniformly cover 
the CTVPlan with 400 cGy dose, and the 380 cGy dose was considered to be the 95% therapeutic 
dose. The CTVPlan had a mean dose of 392.6, a minimum dose of 358.6 cGy, and maximum dose 
of 400.9 cGy. The isocenter dose of this plan was observed to be 399.9 cGy with 94% of the 
CTVPlan receiving the therapeutic (95%) level of dose. We defined the volume that receives the 
95% dose level to be the treatment CTV (CTVT), which is the area encompassed by the red 95% 
isodose lines in Figure 4.1. By definition, the CTVT is completely covered by the 95% dose 
level, and still measures 3 centimeters wide in the direction of motion. For the remainder of this 
work, the CTVT will be referred to as the CTV.  
The plan was exported to the Novalis control station for plan delivery and to the 
ExacTrac control station for imaging setup and gating control. 
4.2.2 Ion Chamber Measurements 
Ion chamber measurements were taken to provide an independent check of the actual 
dose delivered to the CTV. The Quasar phantom also includes an acrylic ion chamber insert 
canister machined to accept an Exradin model A16 micro ion-chamber (Standard Imaging, 
Middleton, WI) with a collecting volume of 0.007 cm
3
. A MK602 electrometer (CNMC 
Company, Nashville, TN) recorded the charge measured by the chamber. The ion chamber 
canister replaces the film insert canister. This canister was modified to insert an imaging coil, so 
that the ExacTrac x-ray setup using implanted fiducials was available. The phantom was 
positioned using the room lasers so that the collecting volume of the chamber was at the machine 
isocenter when inserted into the ion chamber canister. Two ion chamber measurements were 
taken. The phantom was not moving during treatment for the two ion chamber measurements.  
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The ion chamber was calibrated assuming the Novalis machine output was 1 cGy/MU at 
reference conditions. Reference conditions are at 100 SSD at the depth of maximum dose (1.5 
cm for the 6 MV beam of the Novalis accelerator) in a 30x30x2 cm
2
 sheet of solid water with an 
additional 5 cm of backscatter using a 10x10 cm
2
 field size. The chamber was irradiated with 
500 MU (equal to 500 cGy in this calibration setup) in order to calculate the charge collected per 
unit of cGy. Experiment readings were divided by the charge collected per cGy to give the 
corresponding doses. 
4.2.3 Radiochromic Film Phantom Measurements 
The Quasar phantom system also includes an acrylic insert canister for film dosimetry as 
shown in Figure 4.2. Using the treatment planning software, the density of the film canister insert 
was found to be to the same as the acrylic used in the chest wall of the phantom. It provides a 
homogenous material to simplify the treatment planning calculations because the accuracy of the 
TPS heterogeneity correction is irrelevant to this study.  
Figure 4.2 shows views of the Quasar phantom and film canister from the gantry and 
from the foot of the table. This study defines the superior end of the canister and phantom as the 
side towards the foot of the couch. This nomenclature was chosen to provide a comparative basis 
to motion expected in a patient. As a patient moves from full-exhale and begins to inhale, the 
diaphragm is expected to more inferiorly in order to expand the lungs for air intake. Tumors that 
are located in the lungs may have motion strongly influenced by the diaphragm, and the 
diaphragm motion has been shown to be strongly correlated to external markers (4.1). Therefore, 
the motions of external markers are correlated to internal diaphragm motion.  
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Figure 4.2: The Quasar phantom viewed from the gantry (left) and as viewed 
standing next to the foot of the couch (right). Labels denote the superior and 
inferior sides of the phantom. 
Because we have decided to gate at full-exhale, the target would be at its most superior 
position in a patient and motion of the tumor would likely be in the inferior direction. Table 4.1 
is taken from Chi, et al. (4.2) and summarizes the expected motion of a tumor from full-inhale 
(0% phase) to full-exhale (50% phase). By considering the motion of the phantom‟s chest 
platform compared to the motion of the film canister, the phantom‟s respiratory motion is that 
expected of a patient laying supine with feet towards the gantry.  
Table 4.1: The most likely direction of tumor motion from full-inhale to full-
exhale taken from Chi, et al. 
 
 The film canister was modified by milling a small channel into its anterior surface and 
attaching a coil identical to that used in Aim 2. The coil was inserted in the same orientation and 
Superior 
Inferior 
Superior 
Inferior 
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location as in Aim 2. Figure 4.3 shows the outer surface of the canister with the coil in place and 
its position in the phantom.  
Figure 4.4a shows the open film canister with a cut piece of radiochromic EBT film in 
place. The internal surface of the canister contains five pins to facilitate film registration. In 
Figure 4.4b, the registration marks can be seen on the scanned image of a film as dots in the 
corners of the film. The bottom left corner of the canister contains two pins in order to record the 
orientation of the film.  
 
Figure 4.3: (a) Modification of the film insert canister for implanted coil (outlined 
in red) and (b) superior view of canister placement in Quasar phantom with coil 
(outlined in red) on anterior surface of the phantom‟s canister. 
Three plan deliveries were performed and measured with film in the stationary phantom 
in order to establish the repeatability of the phantom setup and irradiation. After each delivery, 
the phantom was moved and the ET system implanted fiducial setup was used to position the 
phantom. For gated treatment delivery, the phantom was set up using the ET software. The 
phantom was positioned on the treatment couch and the motion was set to the desired target 
amplitude. 
a
. 
b
. 
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Figure 4.4: (a) Internal view of film canister with radiochromic EBT film in place 
and (b) sample film showing registration marks from Quasar film canister. 
The ET system captured an image from each x-ray tube at the reference gating level, 
which was set at full-exhale. The user identified the coil endpoints in each image and the ET 
software reconstructed the three-dimensional location of the coil. The ET software then 
calculated a shift to place the treatment isocenter at the machine isocenter. Each time the 
phantom was handled, moved, or changed in any way other than removing the film canister, the 
ET implanted fiducial setup was repeated in order to insure the phantom was properly 
positioned.   
 Gated deliveries of the same treatment plan were performed with a variety of target 
motion amplitudes and gating window levels. The only change from the stationary delivery was 
that the ET software would turn the beam off when the external bodymarkers fell outside the 
gating window. The same treatment plan was delivered every time regardless of the target 
motion or gating window width studied. It was observed that at the smallest gating window of 
10%, no less than 11 MU were delivered during each beam-on segment. A report by Ramsey et 
al. states that machine output, flatness and symmetry do not vary by more than 0.8% in gating 
b
. 
a
.
. 
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sequences when greater than 5 MU are delivered per gate (4.3). However, this was a machine-
dependant test, and must be verified on any machine being commissioned for gated treatment. 
 Experiments were performed with target motion amplitudes of 5, 10, 15, 20, and 25 mm 
and with gating window levels of 10, 20, 30, 50, 80 and 100%. Clinics could potentially use 10-
30% as a gating window width for a patient treatment. Gating windows 50% and 80% were 
selected to show extreme gating window effects. The 100% gating window is essentially a non-
gated delivery with target motion since the beam never turns off, and it demonstrates how 
neglecting the effects of motion affects the delivered dose. In addition to the gated plan 
deliveries, the phantom motion was stopped at full-exhale, and the treatment plan was again 
delivered to the stationary phantom. This resulted in seven separate plan deliveries for each of 
the five amplitude settings. After each nine beam treatment plan was delivered, the film canister 
was removed, and the irradiated film was marked for identification purposes. The film was 
placed in an opaque film jacket inside the film box to allow for 24 hours of self-development 
before scanning and analysis.  
4.2.4 Film Analysis 
For scanning, experiment films were taped to a 14x17” sheet of non-irradiated, processed 
radiographic film to ensure that the experiment films transported smoothly through the Vidar 
film rollers (Figure 4.5). The large film guide also ensured that the experiment films were all 
scanned at the same location in the central portion of the scanner.  One experiment film scan was 
selected as a template for aligning and rotating the scans of all the experimental films scans. In 
this alignment image, the registration marks were vertically aligned. 
 The RIT V5.0 software package was used to analyze the scanned films. On each film, a 
vertical profile was taken along the center of the film. A vertical profile corresponds to the 
direction of motion of the phantom. Any changes to the dose distribution due to phantom motion 
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would be manifested in the vertical direction on the film. The black arrows in Figure 4.6 
demonstrate the direction of the vertical profile recorded for each film. 
 
Figure 4.5: The Vidar film guide used for scanning films irradiated in the Quasar 
film canister. 
Figure 4.6 shows the effect of respiratory motion on delivered dose. The film on the left 
was treated with a 100% gating window (a non-gated delivery) to a target with 20 mm motion 
amplitude. The film on the right was treated without motion and represents the ideal dose 
distribution achievable by the plan delivery.  
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Figure 4.6: Gated delivery with 100% gating level and 20 mm target motion film 
(left) vs. static phantom plan delivery film (right) with black lines symbolizing the 
direction of target motion and analyzed profiles. 
The RIT IMRT analysis software was used to measure profiles through both the reference 
alignment and each experimental film. An example of the analysis is shown in Figure 4.7. The 
green line is an experiment film profile, compared to the red profile which is from the reference 
film where the registration marks were used as a template to align all the experiment films. The 
blue line seen in the profiles measures the difference between the two profiles. The dose of the 
reference film was irrelevant and was discarded. The reference film image was only used for 
alignment purposes for all experimental films. The large needle-like spike seen in the blue 
colored difference profile corresponds to the slight change in the edge of the tape used to affix 
the film into the film guide for scanning.  
Note that the profile is the horizontal profile through the film (perpendicular to the 
direction of phantom motion). There is relatively no change between the profiles, even though 
 79 
the dotted red line is from a 30% gated delivery, and the solid green line is from a static phantom 
delivery with no motion involved.  
 
Figure 4.7: RIT software horizontal profile analysis of 30% window level and 20 
mm motion gated delivery (target) film registered to the (reference) alignment 
film. The target motion was perpendicular to the left profile and to the right in the 
right profile.  
First, the three separate stationary phantom plan deliveries were compared to ensure that 
the registration methods outlined above were correct. If the profiles had the same shape and the 
same location, then the treatment delivery and film analysis methods would be repeatable. 
Vertical dose profiles films from all six gating window deliveries were compared to each 
other and to the stationary phantom delivery for all five target amplitudes. Vertical profiles were 
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exported into Microsoft Excel for plotting purposes. All motion profiles were compared to the 
stationary phantom delivery in terms of displacements of the therapeutic dose (95% dose) levels 
as well as a low dose (20% dose) level expansion. Figure 4.8 shows a sample set of profiles with 
marks to identify the measurements taken from each profile. The black lines at 95% and 20% on 
the left-hand side of the profile indicate an expansion of the gated profiles past the stationary 
profile. This results in increased normal tissue dose. On the right-hand side of the profile, the red 
lines at 95% and 20% indicate that the gated profiles are inside those of the static delivery, and 
the target is being underdosed due to the motion within the gating window. Of the greatest 
importance is the shift in the 95% isodose location that signifies an under-dose delivered to the 
CTV. As previously mentioned, the CTV is the central 3 cm (± 1.5 cm) that is being covered by 
the 95% relative dose level from stationary phantom delivery profile. Respiratory motion of the 
phantom is towards the right-hand side direction in the profile plots, as shown by the gray arrow 
in Figure 4.8. The left hand of the profile is the superior side of the profile and the right-hand 
side is the inferior side, as per our definition of a patient breathing with feet towards the gantry 
breathing with the movements described in Table 4.1.  
The black profile in Figure 4.8 is from the static phantom irradiation, which is the ideal 
CTV coverage. The addition of motion shows obvious deviations from the stationary profile. As 
the size of the gating window decreases, the profiles more closely match the static phantom 
delivery. This is due to the beam being on for a smaller portion of time based around on the full 
exhale position of the phantom. The larger gating windows include more residual motion during 
the time the beam is turned on, so an increasing amount of the CTV is outside the radiation beam 
for a larger amount of time.  
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Figure 4.8: Example of 20 mm motion gated profile measurements in relation to 
static phantom irradiation. The gray arrow represents the direction of target 
motion from the reference gating level at full-exhale. Black horizontal lines 
demonstrate how the 100% gating window expands past the static phantom 
delivery profiles, while red lines indicate a contraction of the dose profile from 
the static delivery profile. 
4.2.5 Margin Expansion Measurements 
 In this research, target motion was uniform, and therefore, the residual motion of the 
target during the gating window was known. As shown in Aim 2, the motion of the coil can be 
tracked to within 0.8 mm of the actual location using the ExacTrac system. The ExacTrac offers 
one way to directly measure the displacement of the implanted fiducial moves during a fraction 
of the breathing cycle.  
Motion 
Inferior Superior 
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 As an initial recommendation, this work evaluated the use of the residual motion during 
the gating window as an internal margin expansion. A 20 mm amplitude motion was selected for 
this test because large deviations from the stationary delivery were observed (Figure 4.19), and 
because treatments with such large respiratory motion would benefit the most gated delivery 
with optimum margin expansions. The Quasar phantom was set up with reference gating level at 
full-exhale and 20 mm target respiratory motion. The residual motion was measured during 
gating window levels of 10, 20, 30 and 100%. Then, for all nine beams, the treatment field size 
was expanded in the direction of target motion by the expected residual motion for a 10% gating 
window level (2 mm), a 20% window level (4 mm), a 30% window level (6 mm), and a 100% 
gating window level (20 mm). These values were calculated from percentage of respiratory 
amplitude that the gating window covers. For example, if the target is moving with a 20 mm 
motion and given a 50% gating window, the target will have a residual motion of 10 mm while 
the beam is on.  
4.2.6 Dose-Volume Calculation 
A dose-volume calculation was performed for a gated plan using a 30% window and 
compared to a plan that does not gate the beam (100% gating window) by encompassing the 
motion of the target. This evaluation used the 20 mm target motion amplitude and the profile 
data from the previous section. The profile expansions for a subset of dose levels (10, 20, 30, 40, 
50, 60, 70, 80, 90 and 95% relative dose) were measured in the direction of motion. Because the 
target motion is parallel to the long axis of the CTV (superior-inferior direction of the phantom), 
the dose distribution in the axial plane will not change significantly. Pinnacle TPS was used to 
find an average area per unit length for various dose levels. Pinnacle TPS was used because the 
experimental film was not wide enough (only 6 cm across) to directly measure the lateral dose 
distribution.  Using the measured profile expansions from the previous section, and the dose area 
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per unit length, we calculated the volumes contained by the selected isodose surfaces. The 
differences in volumes between the gated plan and the non-gated plan will be used to evaluate 
the benefit of using respiratory gating when large (20 mm) respiratory motion is considered.  
4.3 Results 
The Exradin A16 micro ion-chamber measured composite doses of 390 and 396 cGy on 
the two separate deliveries of the nine-beam plan to the stationary Quasar phantom. The three 
repeated stationary phantom plan deliveries to film showed an average dose of 390 cGy across 
the flat, central 3 cm of the profile, which was considered the planning CTV.  The ion chamber 
and film measurements were within 3 cGy or 1% of the mean planning CTV dose (392.6 cGy) 
calculated by Pinnacle.  
For all 9 beams delivered to the phantom in each delivery, no single gated beam took 
longer than 1 minute to deliver, even with a narrow 10% gating window.  The actual treatment 
time to deliver a gated treatment was not significantly increased over a non-gated delivery.  
However, the phantom does not take into account any short-term respiratory irregularities of an 
actual patient, such as coughing, or long term respiratory deviations such a muscle relaxation that 
might lengthen actual treatment times. 
The vertical profiles taken down the central portion of the three stationary phantom 
delivery films are shown in Figure 4.9. For plotting purposes, the center of the each profile was 
considered to be at zero distance. The center was determined by measuring the locations of the 
50% relative dose level and calculating the mean of the two positions. The 95% dose level 
occurs at ±1.5 cm, corresponding to the desired coverage of the 3-cm wide CTV along this 
profile as seen in Figure 4.9.  Each film was normalized to the average dose of all the profiles 
from -1.5 to 1.5 cm, which was 390±2 cGy. Doses were normalized to 390 cGy for all films, 
unless otherwise noted.  
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 The profiles are displayed in terms of relative dose instead of absolute dose to aid in the 
identification of the 95% therapeutic dose level. 
 
Figure 4.9: Film measurements of three repeated stationary phantom plan delivery 
profiles. 
 
As measured from the data in Figure 4.9, the horizontal location of the 95% and 20% 
dose levels from films B and C are within 0.5 mm of the 95% and 20% locations from Film A. 
This result shows that repeated treatments are accurate to within half of a millimeter.  This 
includes all errors from phantom alignment using the x-ray setup process, from treatment 
delivery, and from film registration and scanning.  
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4.3.1 5 mm Motion Data 
The profiles resulting from the 5 mm motion measurements are given in Figure 4.10. 
Table 4.2 shows, for all gating window levels, the measured shift of the profile at the 95% and 
20% relative dose levels. Figure 4.11 and 4.12 are plots of the superior-side and inferior-side 
profile data from Table 4.2. Of particular interest is the 95% dose shift measured on the inferior 
side, where the CTV does not receive the 95% therapeutic dose level.  
For a 5 mm target motion, and small gating windows (≤30%) there is almost no 
difference (≤1 mm) from the stationary phantom irradiation profile. From a dosimetric 
standpoint, gating the beam with a tight gating window (≤30%) achieved nearly the same dose 
profile as the static phantom delivery.  
It should be noted, however, that even when gating is not used (100% window), the 
overall deviation from the static profile is relatively small, due to the small motion of the 
phantom. As noted in AAPM Report 91 (4.4), it may not be necessary for a clinic to perform 
gating on a patient when the respiratory motion is only ~5 mm. It may be easier to simply 
expand the CTV appropriately and to not consider gating. Gating windows of 10-50% resulted in 
CTV under-dose lengths (inferior 95% dose position) of less than 3 mm.  
4.3.2 10 mm Motion Data 
 Figure 4.13 shows the profiles measured with 10 mm of motion for the Quasar phantom. 
The data show the same trends that were exhibited with 5 mm target motion but larger in 
magnitude. Table 4.3 lists the measured shifts in the superior and inferior side of the profiles. 
Figure 4.14 and 4.15 display the isodose shifts from the superior and inferior sides of the 
profiles. Table 4.3 shows that 8.2 mm of the CTV are under-dosed in the 100% gating window 
profile.  
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Figure 4.10: 5 mm dose motion profiles for all measured gating windows. 
 
 
Table 4.2: Measured profile shifts on the superior and inferior side of the 5 mm 
motion profiles at 95% and 20% relative dose levels.  
5 mm 
Superior Profile Shift 
(mm) 
Inferior Profile Shift 
(mm) 
Window 95% 20% 95% 20% 
10% 0.3 0.3 -0.1 -0.1 
20% 1.0 0.8 -0.8 -0.8 
30% 0.4 1.0 -0.6 -0.6 
50% 2.4 2.7 -2.4 -2.2 
80% 2.7 4.2 -4.0 -2.4 
100% 3.1 5.6 -5.4 -2.7 
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Figure 4.11: Plot of 5 mm motion gated superior-side isodose shift. 
 
 
 
 
 
Figure 4.12: Plot of 5 mm motion gated inferior-side profile shift. 
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Figure 4.13: 10 mm motion dose profiles for all measured gating windows. 
 
   
Table 4.3: Measured profile shifts on the superior and inferior side of the 10 mm 
motion profiles at 95% and 20% relative dose levels. 
10 mm 
Superior Profile Shift 
(mm) 
Inferior Profile Shift 
(mm) 
Window 95% 20% 95% 20% 
10% 0.7 0.4 0.5 0.0 
20% 0.4 0.7 -0.2 -0.2 
30% 1.4 1.8 -1.2 -1.1 
50% 2.0 3.2 -2.7 -1.2 
80% 2.0 5.3 -6.1 -2.0 
100% 2.8 8.5 -8.2 -2.5 
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Figure 4.14: Plot of 10 mm motion gated superior-side isodose shift. 
 
 
 
 
Figure 4.15: Plot of 10 mm motion gated inferior-side isodose shift. 
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4.3.3 15 mm Motion Data  
Figure 4.16 shows the profiles measured for the gated delivery using various gating 
window widths as compared to a static phantom irradiation with an identical delivery. Table 4.4 
lists the measured expansions of the gated profiles in comparison to the static profile for the 
superior and inferior side of the target. Figure 4.17 4.18 give graphic representations of the 
superior-side and inferior-side data from Table 4.4. As previously noted, the effect of the gating 
window is more pronounced at larger target amplitudes.  However, the shift of the inferior 95% 
isodose line is still less than 3 mm at the smaller gating windows of 10, 20 and 30%. 
 
 
Figure 4.16: 15 mm motion dose profiles for all measured gating windows. 
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Table 4.4: Measured profile shifts on the superior and inferior side of the 15 mm 
motion profiles at 95% and 20% relative dose levels. 
15 mm 
Superior Profile Shift 
(mm) 
Inferior Profile Shift 
(mm) 
Window 95% 20% 95% 20% 
10% 0.2 0.5 -0.5 -0.4 
20% 0.4 1.6 -1.6 -0.9 
30% 1.6 2.8 -2.3 -1.4 
50% 1.6 5.0 -4.3 -1.6 
80% 2.1 8.9 -9.3 -2.1 
100% 2.5 13.4 -13.5 -3.0 
 
 
 
 
 
Figure 4.17: Plot of 15 mm motion gated superior-side profile shift. 
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Figure 4.18: Plot of 15 mm motion-gated inferior-side profile shift. 
4.3.4 20 mm Motion Data 
Figure 4.19 displays the six measured gated-delivery dose profiles compared to the static 
phantom irradiation. Table 4.5 lists the measured shifts in the superior and inferior sides of the 
profile. At gating windows of 10-30%, the expansion of the 95% dose level past the static profile 
is less than 1 mm. Figure 4.20 and 4.21 plot the measured shifts on the superior and inferior sides 
of the target. As seen in Figure 4.19, the location of the 95% dose level is dramatically shifted 
with the larger gating windows.  
4.3.5 25 mm Motion Data 
Figure 4.22 shows the gated profiles in comparison to the static phantom profile for the 
extreme case of 25 mm target respiratory motion. Using the non-gated (100% window) delivery, 
only a fraction of the CTV, which was defined from ±1.5cm, receives the therapeutic dose 
(95%). Table 4.6 lists the profile expansions measured on the superior and inferior side of the 
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gating profiles. Figure 4.23 and 4.24 give graphic representations of the superior and inferior 
profile shifts.  
 
Figure 4.19: 20 mm motion dose profiles for all measured gating windows. 
 
Table 4.5: Measured profile shifts on the superior and inferior side of the 20 mm 
motion profiles at 95% and 20% relative dose levels. 
20 mm 
Superior Profile Shift 
(mm) 
Inferior Profile Shift 
(mm) 
Window 95% 20% 95% 20% 
10% 0.7 0.9 -1.2 -0.5 
20% 0.4 2.1 -2.5 -0.9 
30% 0.9 3.4 -3.9 -1.2 
50% 2.0 6.4 -6.9 -1.8 
80% 2.5 11.2 -12.3 -2.5 
100% 2.8 16.7 -17.4 -3.2 
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Figure 4.20: Plot of 20 mm motion gated superior-side profile shift. 
 
 
 
 
Figure 4.21: Plot of 20 mm motion gated inferior-side profile shift. 
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Figure 4.22: 25 mm motion profiles for all measured gating windows. 
 
 
 
Table 4.6: Measured profile shifts on the superior and inferior side of the 25 mm 
motion profiles at 95% and 20% relative dose levels. 
25 mm 
Superior Profile Shift 
(mm) 
Inferior Profile Shift 
(mm) 
Window 95% 20% 95% 20% 
10% 1.4 1.6 -0.7 -1.2 
20% 2.0 3.6 -2.5 -2.0 
30% 3.2 5.7 -5.2 -2.7 
50% 3.0 9.1 -8.5 -2.7 
80% 3.0 15.5 -15.8 -2.7 
100% 3.4 21.9 -22.1 -3.7 
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Figure 4.23: Plot of 25 mm motion gated superior-side profile shift. 
 
 
 
Figure 4.24: Plot of 25 mm motion gated inferior-side isodose shift. 
 
0.0
5.0
10.0
15.0
20.0
25.0
0 20 40 60 80 100
Is
o
d
o
se
 s
h
if
t 
(m
m
)
Window (%)
25mm Superior Profile Dose Shift  
95%
20%
-25.0
-20.0
-15.0
-10.0
-5.0
0.0
0 20 40 60 80 100
Is
o
d
o
se
 S
h
if
t 
(m
m
)
Window (%)
25mm Inferior Profile Dose Shift
95%
20%
 97 
4.3.6 Margin Expansion Recommendation 
To evaluate the initial expansion recommendation of using the residual motion for a 
particular gating window, the measurements of the 20 mm inferior profile shifts were 
incorporated into the planning system. The residual motions measured with ExacTrac for gating 
windows of 10, 20, 30 and 100% were 1.7, 3.8, 6.3 and 19.5 mm. These measured values are 
within 0.5 mm of the expected values of 2, 4, 6, and 20 mm. These differences are less than 0.8 
mm, which was the resolution of the ExacTrac system for tracking a moving coil as measured in 
Aim 2. Therefore, 2, 4, 6, and 20 mm were used as one-dimensional expansions in the direction 
of motion for 10, 20, 30, and 100% gating windows. 
A treatment delivery was performed for each plan with the one-dimensional expansions 
incorporated for the respective gating window used. Figure 4.25 shows the central film profile of 
each expanded delivery. Each measured profiles was scaled by the average dose measured across 
its flat central portion. Because the treatment fields were expanded without a change in monitor 
units per beam, the output of each field is increased and potentially results in a higher average 
dose to the target. 
The data show that in the case of 10, 20, 30 and 100% gating window levels, expanding 
the treatment field by the residual motion in the direction of motion results in overdose to some 
normal tissue in the direction of motion. In the case of the 10% gating window expansion, the 
treatment field was only expanded by 2 mm and seems to have a negligible difference from the 
static delivery. 
Table 4.7 shows that using the residual motion of the target during the gating to expand 
the treatment field is larger than necessary. On the inferior side of the profile, for example, the 
non-expanded fields under-dosed the inferior side of the profile by 3.9 mm at the 30% gating 
window, but the 6 mm expansion increased the profile past the static phantom profile by 4.3 mm. 
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The superior-side profiles in Figure 4.26 are relatively unchanged from Figure 4.20 because this 
side of the treatment field was not expanded. The significant change is the overexpansion of the 
gated profiles past the static phantom profile on the inferior side.  
 
 
Figure 4.25: 20 mm amplitude motion gated deliveries expanded in the direction 
of target motion by the residual motion during the gating window. 
The main goal of the margin expansions is to provide adequate coverage of the CTV as it 
moves away from the full-exhale position that the reference gating level is set to. It should be 
noted in all of the profiles that the gating window also shifts the dose profile past the static 
delivery on the superior side. This could signal the possibility of shrinking the margins slightly 
on the superior side of the target, but this was not considered in the margin expansion 
recommendations used in this project. 
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Table 4.7: Amount of overexpansion (in mm) beyond the static profile when 
expanding by the residual motion for the 20 mm motion plan delivered with 10, 
20, 30 and 100% gating windows. 
Superior Profile Shift (mm)  Inferior Profile Shift (mm) 
Window 95% 20%  Window 95% 20% 
10% 1.1 1.2  10% 0.7 0.9 
20% -0.4 1.1  20% 2.7 3.9 
30% 0.5 2.3  30% 4.3 6.2 
100% 1.2 16.0  100% 2.9 17.8 
 
This project then evaluated expanding the treatment field in the direction of motion by 
the measured distance of under-dose of the 95% therapeutic dose level on the inferior side of the 
profile using Table 4.5 for the 20 mm target motion. For a treatment with a gating window of 
30%, a one-dimensional field size expansion of 3.9 mm was incorporated in the direction of 
phantom motion for all nine beams. For treatments that would use gating window widths of 50, 
80 and 100%, field size expansions were made for the delivery plan in the direction of motion for 
all nine beams by 6.9, 12.3, and 17.4 mm, respectively. It should be noted that for a 20 mm 
uniform target motion, the residual motions of the target during 30, 50, 80, and 100% gating 
windows are 6, 10, 16 and 20 mm, respectively. As seen in Figure 4.19, the effects of the gating 
window were to contract the measured inferior dose profile inside the static phantom profile. By 
expanding these fields, the 95% dose coverage should be re-achieved as seen in the static 
phantom plan delivery. 
 Four (30, 50, 80, and 100% gating window level) gated 95%-inferior-dose-shift-
expanded plans were delivered to the Quasar phantom. A static phantom delivery of the original, 
non-expanded plan was also performed. Figure 4.26 shows the corresponding profiles through 
each of the 4 gated/expanded plans and 1 static phantom delivery as described above.  
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Note that the superior (left-hand) side of the profiles remains unchanged from the non-
expanded, gated deliveries as previous seen in Figure 4.19. As expected on the inferior side of 
the dose profiles, the 95% dose levels for all 4 margin-expanded deliveries are within 0.8 mm of 
the 95% dose level of the static phantom delivery profile. This is nearly within the 0.5 mm error 
limit established from the three stationary profiles from Figure 4.9. By incorporating the 
project‟s recommended expansion into the plan delivery, for a 20 mm target motion, similar 
therapeutic dose coverage of the target was obtained as that of a plan delivered to a stationary 
phantom. 
It should be noted that using a larger gating window results in needing a larger expansion 
to cover the target. The residual motion increases proportionately to the gating window. The 
larger residual motion has the disadvantage of delivering dose to larger amounts of normal 
tissue, as seen in the (low dose) profile expansions in Figure 4.26. This work recommends 
balancing using as small a gating window as possible without over-extending the amount of time 
the plan delivery takes due to the smaller beam-on time per respiration. 
Table 4.8 lists the recommended margin expansions for various gating windows based on 
the measured 95% dose profiles. Table 4.9 shows the difference between the data shown in Table 
4.8 and the residual motion for each gating window. For a 5 mm and 10 mm target motions, the 
recommended internal margin expansion is less than 3 mm for gating windows up to 50%. At 15 
mm target motion, 10, 20, and 30% gating windows have a recommended margin expansion of 
less than 3 mm. For 20 mm and 25 mm target motion, the recommended expansion is less than 3 
mm only for the 10 and 20% gating window widths. 
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Figure 4.26: 95% dose shift expansion profiles for 30, 50, 80 & 100% gating 
windows compared to the static phantom delivery. 
 
Table 4.8: Summary of the recommended internal margin expansion based on the 
size of the 95% under-dose on the inferior side of the gated profile. Gating 
windows which have a recommended internal margin expansion less than 3 mm 
for each target motion observed are marked in light green. Gating windows which 
have a recommended margin larger than 3 mm are marked in light red.  
  Recommended margin expansion 
Target Motion (mm) 
Gating window 
 
10% 20% 30% 50% 80% 100% 
5 0.1 0.8 0.6 2.4 4.0 5.4 
10 0.5 0.2 1.2 2.7 6.1 8.2 
15 0.5 1.6 2.3 4.3 9.3 13.5 
20 1.2 2.5 3.9 6.9 12.3 17.4 
25 0.7 2.5 5.2 8.5 15.8 22.1 
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Table 4.9: Difference of recommended margin based on the 95% dose profile 
shift and the residual motion.  
Target Motion 
(mm) 
Gating window 
10% 20% 30% 50% 80% 100% 
5 -0.5 -0.3 -1.1 -0.4 -0.4 -0.1 
10 -0.5 -1.8 -1.8 -2.3 -1.9 -1.8 
15 -1.0 -1.4 -2.2 -3.2 -2.7 -1.5 
20 -0.8 -1.5 -2.1 -3.1 -3.7 -2.6 
25 -1.8 -2.5 -2.3 -4.0 -4.2 -2.9 
 
4.3.7 Dose-Volume Calculation 
The expanded profile data shown in Figure 4.26 were used to estimate increased volumes 
receiving each dose level (10-95%). While the 95% CTV dose coverage is approximately equal 
between treatments of a non-gated delivery and a gated delivery, the volume receiving low dose 
(20%) is increased as an effect of the target motion. This determined the total volume per dose 
level for a motion-encompassed plan (100% window) and a gated plan (30% window).  
Table 4.10 lists the calculations for the plan using a 30% gating window for the dose 
volumes for a range of dose levels from 10-95%. The “Profile Width” column is the measured 
overall profile width from Figure 4.26 to estimate the longitudinal dimension for each isodose. 
“Pinnacle Area/Length” is the estimated area per unit length of each dose level. The column 
labeled “Dose Volume” is the calculated dose volume using the profile width multiplied by the 
area per unit length. 
Table 4.11 and Table 4.12 show similar data as Table 4.10  using Figure 4.25 to calculate 
the profile width for the case of the motion (20 mm) encompassed delivery and the static 
delivery, respectively. The area per unit length calculated from Pinnacle is the same as in Table 
4.10, because the effect of the dose shift is in the axis along the direction of motion. Therefore, 
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the axial dose distribution was considered unchanged for the purposes of this calculation. The 
total volume was calculated from the product of profile width and pinnacle area per unit length. 
Only the length of the dose volumes changed due to motion within the gating window. 
Figure 4.27 shows that the volume of tissue receiving 20% of the dose is approximately 
35% less with 30% gating window delivery than the with motion-encompassed (100% window) 
delivery. Compared to the static phantom delivery, there is a small increase (approximately 15%) 
in the 20% dose volume with the 30% gating window delivery. By accounting for the effects of 
motion with respiratory gating, we can reduce the effect of motion on the delivered dose. From 
this figure, it is clear that motion-encompassed delivery can adequately cover a target moving 
with respiration, but the amount of normal tissue receiving low doses is elevated over that of a 
gated treatment delivery. 
 
Table 4.10: Calculated dose volume data for a 30% gated delivery expanded to 
cover the CTV. 
  Profile Pinnacle Dose 
Dose 
 
Width 
(cm) 
Area/Length 
(cm) 
Volume 
(cm
3
) 
% 30% 30% 30% 
10 5.13 273.1 1399.8 
20 4.63 234.5 1085.3 
30 4.43 107.5 476.4 
40 4.29 32.1 137.6 
50 4.13 20.9 86.2 
60 3.99 11.1 44.4 
70 3.83 12.2 46.6 
80 3.61 10.3 37.1 
90 3.31 8.6 28.4 
95 3.06 7.0 21.5 
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Table 4.11: Calculated dose volume data for a motion-encompassed (100% 
window level) delivery (20 mm) expanded to cover the CTV. 
 Profile Pinnacle Dose 
Dose 
Width 
(cm) 
Area/length 
(cm) 
Volume 
(cm
3
) 
% 100% 100% 100% 
10 7.57 273.1 2065.7 
20 7.14 234.5 1673.9 
30 6.78 107.5 729.0 
40 6.28 32.1 201.5 
50 5.62 20.9 117.4 
60 5.02 11.1 55.9 
70 4.40 12.2 53.6 
80 3.77 10.3 38.7 
90 3.44 8.6 29.5 
95 3.19 7.0 22.4 
 
 
 
Table 4.12: Calculated dose volume data for a static phantom delivery. 
  Profile Pinnacle Dose 
Dose 
Width 
(cm) 
Area/length 
(cm) 
Volume 
(cm
3
) 
% Static Static Static 
10 4.55 273.1 1242.4 
20 4.03 234.5 945.1 
30 3.9 107.5 419.2 
40 3.79 32.1 121.6 
50 3.71 20.9 77.4 
60 3.63 11.1 40.4 
70 3.56 12.2 43.4 
80 3.45 10.3 35.4 
90 3.23 8.6 27.7 
95 2.99 7.0 21.0 
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Figure 4.27: Calculated volumes receiving a range of dose levels shown for a 
comparison of a 30% window gated plan, motion-encompassed (100% gating 
window) plan, and a stationary phantom delivery with no expansion.  
 
4.4 Conclusions 
This aim demonstrated that mean target doses measured with radiochromic film and ion 
chamber measurements agree with Pinnacle-calculated dose to within 1%, and that ExacTrac 
gating x-ray setup and delivery is accurate to 0.5 mm. We also found that margin expansion in 
the direction of motion by the expected residual motion proved to be larger than necessary. 
Coverage of the CTV by 95% dose level was found to be achievable with smaller expansions for 
all motions and gating windows. The trends of the measured dose profile from each motion 
amplitude behaved as expected with smaller gating windows producing profiles that more 
closely matched the shape of the static phantom delivery profile.  
An estimate of the phantom volume irradiated with a conventional non-gated plan was 
compared to a gated plan utilizing a 30% gating window for a cylindrical target with 20 mm 
0
500
1000
1500
2000
2500
0 20 40 60 80 100
A
b
so
lu
te
 V
o
lu
m
e 
(c
m
^
3
)
Relative Dose Level
20mm Motion DVH Example
30% Gating Window
Motion Encompassed
Static Delivery
 106 
respiratory motion. The CTV coverage achieved with both plans was comparable. However, the 
volume of tissue receiving 20% of the prescription dose was 35% less for the gated delivery than 
for the non-gated one. This example demonstrated the ability of gated therapy treatments to spare 
more normal tissue while maintaining adequate target coverage.  
 Dose profiles on the superior side of the moving phantom expanded past the static 
phantom profile, and these margins could in theory be decreased. However, the values of over-
expansion on the superior side of the profile were small enough that the potential decrease of 
those margins was not studied. 
 This aim demonstrates that using the expected residual motion for margin expansion 
provides proper target coverage but still irradiates more normal tissue than is optimal. However, 
the optimal margin expansions measured in this project were limited to a single, simple beam 
arrangement and a phantom moving in a simple predictable pattern. For patient treatments, the 
expected residual motion should be used for margin expansion, unless patient-specific 
measurements are available that demonstrate proper coverage from a smaller expansion. 
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5 Conclusions 
5.1 Aim 1 
Both the Epson and Vidar scanners showed equivalent performance in terms of scanner 
repeatability, uniformity, and noise. The Epson scanner performed better than the Vidar scanner 
in a few categories such as scanner/film noise and scanner uniformity of a blank sheet of film.   
One problem with the Epson scanner is the lack of self-calibration of the light source or 
warm-up test. The user must simply take many preview scans with the Epson scanner and 
assume the scanner is adequately warmed up. Other issues are the lack of support from the Epson 
Corporation in regards to medical physics applications and the lack of FDA clearance. Without 
FDA constraints, graphic arts scanner manufacturers can substitute components and firmware 
without notice, possibly resulting in significant differences between scanners. Finally, the lack of 
adequate commercial software for film dosimetry is a major disadvantage. 
With the Vidar scanner, a problem was observed with the leading and trailing edges of a 
scanned film. The leading and trailing edge of the film profile perpendicular to the light source 
measured a 3% increase in pixel value. The artifacts can be avoided by ignoring the leading and 
trailing inch of film in a film scan, or by affixing a piece of film to a larger film guide for 
transportation through the Vidar scanner. The EBT manufacturer recommends, and will provide, 
a clear polyester sleeve to secure the film (both cut film pieces and whole sheets) when using the 
Vidar scanner. We found these sleeves to be unacceptable because of circular Newton ring 
artifacts. When small pieces of cut film are to be analyzed in the Vidar system, they should be 
attached to a larger film guide for transportation through the Vidar scanner. When a film guide is 
not used, the leading and trailing inches in the scanned image should not be used.   
All film analysis in this project allowed 24 hours between irradiation and scanning. There 
was no evidence that 24 hours was required, but this time frame was convenient for this work.  
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Many reports in the literature use a smaller time interval, such as six hours. The film 
manufacturer recommends waiting at least two hours after irradiation to scan EBT film.  
Film-to-film variations within a single batch were very low with a standard deviation of 
the film response less than 0.51 percent. Therefore, a single calibration film is adequate for an 
entire batch. However, batch-to-batch variation was significant, so that each batch must be 
individually calibrated. 
5.2 Aim 2 
From 4DCT studies of the measured coil length it was determined that at end-respiration 
(full-exhale and full-inhale), motion induced coil artifacts were less than a millimeter. This 
works demonstrated that when identifying a coil on phase-sorted CT datasets, a user can locate 
the coil endpoints with a variation less than 0.5 mm. This aim concluded that 4DCT phase-sorted 
datasets corresponding to full-exhale and full-inhale would provide the most accurate image of 
the moving phantom. Due to the mechanics of breathing, exhalation in actual patients is usually 
more stable and reproducible than inhalation. This project recommends using a full-exhale 
dataset for treatment planning system calculations and gating the radiation treatment about the 
full-exhale (50%) phase of respiration.  
When determining the extent of a phantom‟s respiratory motion with an implanted 
surrogate such as a coil, the ExacTrac system performs better than 4DCT at coil localization. To 
accurately determine the direction and extent of phantom‟s internal respiratory motion after coil 
implantation, this aim recommends using the ExacTrac system. The ExacTrac can localize a 
moving coil to within 0.8 mm of the expected position, while 4DCT registered errors up to 5.5 
mm from the expected coil endpoint position. 
For a patient with well-behaved (e.g., no coughing, gasping, or sudden motions) chest 
wall motion, this work suggests that the ExacTrac system can localize an implanted coil to 
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within 1 mm. Thus, for patients with an implanted coil, the extent of tumor motion could directly 
be measured for use in treatment planning and selection of gating parameters. 
5.3 Aim 3 
This aim demonstrated that mean target doses measured with radiochromic film and ion 
chamber measurements agree with Pinnacle-calculated dose to within 1%, and that ExacTrac 
gating x-ray setup and delivery is accurate to 0.5 mm. We also found that margin expansion in 
the direction of motion by the expected residual motion proved to be larger than necessary. 
Coverage of the CTV by 95% of the isocenter dose was found to be achievable with smaller 
expansions for all motions and gating windows.  
An estimate of the phantom volume irradiated with a conventional non-gated plan was 
compared to a gated plan utilizing a 30% gating window for a cylindrical target with 20 mm 
respiratory motion. The CTV coverage achieved with both plans was comparable. However, the 
volume of tissue receiving 20% of the prescription dose was 35% less for the gated delivery than 
for the non-gated one. This example demonstrated the ability of gated therapy treatments to spare 
more normal tissue while maintaining adequate target coverage.  
 Dose profiles on the superior side of the moving phantom expanded past the static 
phantom profile, and these margins could in theory be decreased. However, the values of over-
expansion on the superior side of the profile were small enough that the potential decrease of 
those margins was not studied. 
 The results demonstrate that using the expected residual motion for margin expansion 
provides proper target coverage but still irradiates more normal tissue than is optimal. However, 
the optimal margin expansions measured in this project were limited to a single, simple beam 
arrangement and a phantom moving in a simple predictable pattern. For patient treatments, the 
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expected residual motion should be used for margin expansion, unless patient-specific 
measurements are available that demonstrate proper coverage from a small expansion. 
5.4 Recommendations 
This work has demonstrated that in a simple system, margin expansion based on residual 
motion during gating provides proper target coverage with reduced normal tissue dose compared 
to non-gated delivery. Extrapolating to patient treatments suggests that target margins should be 
set using the residual motion during gating. For patients without implanted coils, the residual 
motion can be computed based on the target motion measured from 4DCT and the size of the 
gating window. For patients with implanted coils, the ExacTrac system can be used to directly 
measure residual tumor motion during gating.  
5.5 Response to Hypothesis 
The hypothesis of this work was that gated delivery combined with 4DCT could limit 
internal margins to less than 3 mm while maintaining 95% prescription dose coverage of moving 
targets. The hypothesis was found to be true for gating windows of 10% and 20% for target 
motions up to 25 mm.  For smaller motions (5mm and 10 mm), it was true with gating windows 
up to 50%.  
5.6 Future Work 
 One limitation of this work was the use of a one-dimensional respiratory phantom. The 
sinusoidal motion utilized throughout this study allowed for predictable and repeatable testing, 
but a patient will exhibit neither characteristic.  The next step of this work is to repeat the coil 
localization studies on an anthropomorphic phantom which can mimic actual patient motion in 
more than one dimension. The film measurements and margin recommendations in Aim 3 
conclusions should be extended into three-dimensional motion. The effect of patient respiratory 
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irregularities on the delivered dose should also be characterized before designing gated 
treatments for patients.  
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